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ABSTRACT 
 
 
This study explored the relationship of a dinucleotide repeat polymorphism in the 
intron of the CRP gene and serum CRP levels as independent risk factors for end-organ 
dysfunction (mild vs. severe) in adults with sickle cell disease. The pathogenesis of 
secondary complications of sickle cell disease is complex and poorly understood. 
Predicting the severity of these complications could assist in therapeutic decision-
making.  
 
The study measured serum CRP levels and the number of CA intron repeats 
located on the CRP gene in 29 adults (31.74 ± 11.54 years) with sickle cell disease The 
hemoglobin genotypes were distributed as Hgb SS 48.6% (17 of n = 29), Hgb SC 20.0% 
(7 of n = 29), Sβ° 10.3% (3 of n = 29), and Sβ+ 6.9% (2 of n = 29). The sample was 
categorized as mild (n = 9) no end-organ dysfunction vs. severe (n = 21) documented 
end-organ dysfunction. The severe group was sub-categorized by specific organ 
dysfunctions, 9 with pulmonary hypertension, 6 with renal dysfunction and 6 with 
cerebral vascular accident. Examination of serum CRP levels found no significant 
association with severe end-stage organ dysfunction. There was no significant association 
between serum CRP level and the polymorphism. However, a significant negative 
correlation (rho = -0.401,   p = 0.031) was found between glomerular filtration rates and 
CAhigh repeats (≥17). 
 
Previous studies have found an association of genetic variations in the CRP gene 
polymorphism to serum CRP levels. While this pilot study found no evidence of this 
association, the findings provide some rationale for further investigation of the repeat 
polymorphism in the CRP gene and its association with renal end-organ dysfunction. 
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CHAPTER 1. INTRODUCTION 
 
 
Overview 
 
 One in 400 African-Americans and millions of people worldwide are affected by 
the single gene autosomal recessive hemoglobinapathy of Sickle Cell Disease (SCD) [1]. 
Advances in childhood treatments have increased the life expectancy of patients with this 
disease into the 4th and 5th decade of life [2]. Despite these advances, an elevated 
morbidity and early mortality risk remain through adulthood, in large part because of 
secondary complications resulting in cumulative end-organ damage.  
 
 Development of chronic organ dysfunction is a more powerful predictor of early 
mortality than frequency of acute painful episodes [3-5]. Secondary complications and 
damage can be found in the cerebral, pulmonary, renal, and retinal vascular territories in 
these patients [2]. The high mortality and morbidity rates are due to the underlying sickle 
disease process resulting in micro-vascular occlusions caused by interactions between 
sickle red blood cells, white blood cells, humoral factors and vascular endothelial cells. 
Identification of risk factors associated with organ damage would facilitate earlier 
identification of SCD patients at risk for dysfunction and complications, and justify 
earlier and more aggressive therapy.  
 
 Any organ with a blood supply is susceptible to damage. However, the most 
common target organs for SCD are the brain (ischemic and hemorrhagic stroke), lungs 
(pulmonary hypertension), kidneys (protein-losing nephropathy and end-stage renal 
disease), and retina (proliferative retinopathy) [2, 4, 6]. The full extent of organ 
dysfunction in patients with SCD is only now being recognized from recent studies of 
adult populations [4, 7, 8]. A new severity score has been developed to evaluate the 
complexity of problems in SCD patients [9] but has not been independently validated. 
Consequently, there is a need to identify risk factors to improve SCD risk prediction. 
 
 The etiology of end-organ damage is probably multi-factorial, likely to include 
pro-inflammatory pathways and genetic factors that mediate the inflammatory phenotype 
[4, 5, 10, 11] . A serum laboratory test of C-Reactive Protein (CRP) elevation is routinely 
measured in a variety of disease processes as a marker for inflammation [12] and may be 
a marker for end-organ damage in SCD. In addition, a polymorphism in the C-reactive 
protein (CRP) gene, that may regulate the expression levels of serum CRP may be one 
factor in the etiology of end-organ damage [13, 14] and has been explored in 
atherosclerosis, diabetes, and systemic lupus [13-18], but not in SCD.   
 
 Recent data suggest that the elevated biomarker of high sensitivity (hs)-CRP may 
provide predictive information for risk of cardiovascular disease and other inflammatory 
diseases in the general population [19, 20]. One of these risk factors may be an abnormal 
response of hs-CRP to sub-clinical vascular inflammation from micro-occlusions that is 
seen in other inflammatory diseases [20]. One study showed CRP levels were more 
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frequently elevated in baseline SCD patients and the alteration might be provoked by a 
low-grade inflammatory process [21].  
 
 This elevated serum biomarker does have a genetic component that may mediate 
the serum blood levels [12]. To date, few studies have looked at the CRP gene as a 
biomarker of severity of end-stage organ disease in the adult with SCD. Findings 
demonstrate that adults with homozygous, (Hgb SS) and heterozygous (Hgb SC) sickle 
hemoglobinapathy may have an abnormal elevation of serum hs-CRP levels associated 
with a polymorphism such as a microsatellite repeat in the intron of the CRP gene that 
exacerbates the natural function of the gene, compounding their underlying 
hemoglobinopathy [1, 22]. This biomarker and polymorphism may be useful in the 
definition of severity levels of end-stage organ dysfunction. They may also enhance risk 
assessment and offer new insights. 
 
 
Specific Aims 
 
The purpose of this study is to access the utility of CRP polymorphism and serum 
levels as an independent risk factor for end-organ dysfunction in SCD. The study will 
describe and characterize two groups of adults with SCD (mild and severe) according to 
historical and clinical markers. Additionally, the data will be used to explore the use of 
the newly developed Sebastiani Network Model (SNM) Severity Score [9].   
 
The primary aims were to: 
 
1. Describe and characterize two groups of sickle cell disease (SCD) patients with 
(severe cases) and without (mild cases) the development of chronic organ 
dysfunction. Then use the data to validate the predictive value of the SNM Severity 
Score. 
2. Assess whether serum CRP levels differ between two groups of SCD patients, with 
(severe cases) and without (mild cases) the development of chronic organ 
dysfunction.  
3. Assess whether genotype profiles for a microsatellite repeat in the intron of the CRP 
gene differ between two groups of SCD patients, with (severe cases) and without 
(mild cases) the development of chronic organ dysfunction. 
 
a. Identify the microsatellite repeats in the intron of the CRP gene for severe cases. 
b. Identify the microsatellite repeats in the intron of the CRP gene for mild cases. 
c. Assess whether the microsatellite repeat in the intron of the CRP gene is 
associated with serum CRP levels in the two groups of SCD patient with (severe 
cases) and without (mild cases) the development of chronic organ dysfunction. 
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Significance 
 
 In the United States, one in 600 people have SCD with the genotype of 
hemoglobin SS (Hgb SS). Other common genotypes are hemoglobin C (Hgb SC) and β-
thalassemia (Hgb Sβ+/0), which together are as common as Hgb SS. Additionally, one in 
10 African Americans (AA) are heterozygous carriers of Hgb SS and recent literature 
suggests that this trait may not be as benign a condition as once thought [23]. Advances 
in the treatment of SCD have led to expanding survival rates into the 4th decade of life for 
SCD patients [5]. With increased survival rates, patients are experiencing more secondary 
complications of chronic organ dysfunction. The exact etiology is unknown; but 
inflammation may play an important role.  
 
Inflammation and abnormal adhesion of sickled cells are thought to contribute to 
vascular occlusions that lead to chronic organ dysfunction [5, 10, 21, 24]. CRP induced 
inflammation is an acute phase response to vascular damage. Serum CRP levels are a 
newly recognized serum biomarker for vascular damage [19, 25, 26] but little literature 
addresses the utilization of CRP levels in assessing potential end-organ dysfunction in 
SCD patients [21].   
 
Reliable and accurate screening and preventive therapies are needed to identify 
patients at the greatest risk for secondary complications. Traditional screening with serum 
biomarkers and radiological technology are being explored as tools in risk assessment of 
adult SCD patients; however, there is no consensus on which tools yield the most 
accurate risk assessment.   
 
Another emerging tool will be the exploration of genetic mutations and common 
polymorphisms, which may alter expression profiles. The advancement of genotyping 
technology has made progress as a screening tool in the identification of patients at risk 
for complex disorders [13, 15, 27]. This study will utilize the candidate gene approach to 
explore a common microsatellite in the intron of the CRP gene and its association to 
serum CRP levels. Exploration of a common polymorphism found to be more prevalent 
in the AA population [12] may advance the understanding of its clinical significance.  
 
Treatment of multi-factorial diseases such as nephropathy, pulmonary 
hypertension, and cerebral vascular accidents and SCD by conventional means requires 
identification of the roles each factor contributes to the disease process and understanding 
the pathophysiology of the disease. Assessment of risk factors involved in multi-factorial 
disease impacts treatment and the patient’s personal assessment of how they view of 
health.  
 
All possible avenues for identification of this at risk SCD population need to be 
verified and explored. These patient’s risks need to have a quantifying score to assist in 
healthcare utilization and maintenance. Promoting self-care and healthy life style choices 
will be crucial to patients with a chronic illness to maximize their quality of life. 
Understanding all complex interacting factors will be valuable to promote an improved 
healthy life-style. 
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It is imperative for health care providers to establish a multidisciplinary approach 
for effective and efficient health care. Nurses are poised to play a pivotal role in the 
delivery of care through their skills in research, patient-provider interaction and 
interpretation of bench to bedside care. One nursing role is to bridge the existing gaps 
between the geneticists, primary care providers, and the patient population. Another role 
will be the ability to identify and develop genetically based educational materials 
addressing the complex issues of SCD.  
 
This research may supply the clinical providers with vital screening information. 
This assessment information could identify individuals with the greatest risk for end-
organ dysfunction. Healthcare providers could determine which individuals may benefit 
from dietary restrictions, nutritional or vitamin supplementation and drug therapy which 
could impact the care of this vulnerable population. The long term goal of clinical 
providers is to promote the health of patients with SCD and that nursing research would 
be part of accomplishing that goal. Such research will integrate genetics, and risk 
assessment of end-stage organ damage, in SCD, leading to programs for more efficient 
health care utilization, and improved morbidity and mortality rates in this vulnerable 
population. 
 
 
Conceptual Framework 
 
Healthcare providers believe risk assessment involves the physical body and the 
physical environment. They judge the amount of risk and attempt to adjust the 
environment to decrease risk [28]. Analyzing data depends on prior knowledge and is 
necessary to process any given information such as physical conditions, environment and 
risk factors. Healthcare providers likely have knowledge the patient has not acquired. 
Patient knowledge and understanding of facts as presented influences patient decisions 
and health care choices. Healthcare providers and patients view the impact of risk 
assessment differently. Within healthcare, risk is the notion that extends the clinical view 
beyond the physical body and into the domain of the environment. Healthcare providers 
identify the scope of risk and attempt to regulate the patient’s environment to decrease 
risk [28]. By analysis of the concept of risk, it has been determined that to acknowledge 
risk is necessary to process the concept.  
 
According to Huber, et al. (1997), risk research reveals that many aspects are 
relevant to patients. Subjective patient perception and patient evaluation of risk 
influences the understanding of negative outcomes and subjective probability. This 
concept may explain why patients continue to choose behaviors that healthcare providers 
identify as risk inducing. These chosen behaviors are not perceived as a risk to the 
decision maker. Prior knowledge, personal experience, education, and environment are 
influencing factors in the decision making process. Presenting risk information enables 
patients to understand choices and empowers them in the decision making process [29, 
30]. 
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The patient must have the cognitive ability to distinguish between two or more 
choices and the consequences of the choices. Patient cognitive ability, evaluation, and 
education will be necessary to enhance the patient’s decision-making process. 
Information overload and patient request for information should not be confused with 
their decision-making process or their assessment of risk/benefit ratios. 
  
There are accepted terms used to define risk that focus on judgment and decision-
making [28]. Risk is a measurable uncertainty and is usually related in statistical 
percentages. When patients recognize and accept that understanding of risk, information 
then becomes more meaningful in their judgment and decisions in relation to risk-taking 
[31]. According to Kraemer, et al (1997), “a risk factor is a measurable characteristic of 
each subject in a specific population that precedes the outcome of interest” (p.337) [32]. 
Society now associates risk with negative outcomes, especially in healthcare. “The 
concept of risk is the uncertainty surrounding the translation of scientific knowledge into 
clinical practice” (p.5), [31]. Risk precedes the threat of a negative outcome. Jacobs 
identifies three epidemiological conceptions of risk, absolute risk, relative risk and 
attributable risk [31]. Patients assessing risk must view the impact of risk as important 
and meaningful enough to influence judgments. Decisions need to be made in relation to 
recognizing the outcome of risks taken. 
 
Risk estimation is another term used generically for risk factors [32]. Weight of 
evidence, is also a term often used in the discussion of risk assessment [33]. Decision 
research is the amount and accuracy of information gained to assess the risk of decisions 
[34]. Non-adherence is another related term pertaining to risk. Chater (1999) states “the 
notion of non-adherence has been classified as risk-taking behavior, which can be 
modified if the individual adheres to medical advice” (p.136) [28]. Clearly defined risk 
concepts include but are not limited to risk relationship to health outcomes, one model 
that uses the construct is the Interaction Model of Client Behavior. This model, see 
Figure 1.1, will provide the framework for this proposal and future research [35]. 
 
The Interaction Model of Client Health Behavior is abstract in nature and is 
defined by three major elements: client singularity, client-professional interaction, and 
client health outcomes. First, the client singularity element includes background variables 
of demographic characteristics, social influence, previous health care experience, and 
environmental resources. Within this abstract element there are variables of intrinsic 
motivation, cognitive appraisal, and affective response. These constructs are defined as 
independent of each other but having temporal order and mutual interactions. All are well 
defined but still abstract in definition. They can be operationally developed into 
measurable variables. This element emphasizes the holism and uniqueness of the 
individual. 
 
 Second, the client-professional element accentuates numerous factors that define 
nursing interventions. The broad concepts are affective support, health information, 
decisional control, and professional/technical competencies. Affective support includes 
supplying emotional support, assessment of motivation, and specificity of health 
information given to the patient. Health information includes both giving and receiving  
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Figure 1.1 Interaction Model of Client Health Behavior 
Reprinted with permission. Cox, C.L., Online exclusive: a model of health behavior to 
guide studies of childhood cancer survivors. Oncology Nursing Forum, 2003. 30(5): p. 
E92-9 [35]. 
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information. Health care providers must persistently review current research and improve 
methods of providing appropriate patient education. Nursing and other health care 
providers can take research from bench to bedside to facilitate desired health outcomes. 
Healthcare providers can direct decisional control, but patients must or should take 
ownership of risk taking decisions, based on informed consent, when there are 2 or more 
choices. Patient perceived professional/technical competencies of healthcare providers 
are crucial to their decision making process. 
 
The third element, client health outcomes include utilization of health care 
services, health indicator status, severity of health problems, adherence to treatment plans 
and satisfaction with current care [35-37]. Health outcome elements are very broad and 
allow maximum flexibility in efforts to facilitate nursing research by operationally 
defining outcomes to care received [35, 36].  
 
 Measuring variables within the Interaction Model of Client Health Behavior, see 
Figure 1.2, involves using four multi-factorial areas that impact the risk factors for 
secondary complications in sickle cell disease. They are genotype, phenotype, clinical 
health status indicators and severity of healthcare problems. These are interactive risk 
factors that influence the degree of risk experienced. How these factors interact exerts 
control and affects the levels of risk and the development of secondary complications. 
These factors influence risk levels. The conceptual framework for this study from the 
Interaction Model of Client Health Behavior [35, 36] demonstrates the interrelationship 
of these factors and how they may affect the health outcomes of the sickle cell disease 
(SCD) population.    
 
 This study was a stepping-stone to identification, definition and exploration of 
genetic risk. The microsatellite factor interacts with serum CRP to affect phenotype. 
Phenotype and genotype interact to affect severity of healthcare problems. These 
variables can influence the degree of risk, evidenced by the severity score that patients 
are willing to accept. The outcomes of the study, validation of severity scores for patients 
with SCD, the association of serum CRP levels, and prevalence of a genetic CRP 
microsatellite are key to the central concept of risk. The relevance of risk to the sickle 
cell population will influence the advances in SCD research. Well-informed and educated 
patients can make informed health care choices when utilizing healthcare services. 
Patient education includes the amount and type of information presented to the patient. 
Education is essential in the decision process involving risk and impacts adherence to 
recommended care regimens and satisfaction with care. This concept then becomes 
crucial to development and tailoring of programs, education and interventions that meet 
the antecedents of risk in decision-making in order to achieve successfully the elements 
of health outcomes. 
 
The purpose of the study was to assess serum CRP levels and a microsatellite in 
the intron of the CRP gene and its association to SCD patient groups with (severe cases) 
and without (mild cases) chronic organ dysfunction using a candidate gene approach.  
These are measurable characteristics of chronic organ dysfunction and may be useful in 
describing and characterizing the phenotype for secondary complications in patients with  
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Serum CRP levels Severity score
Identification of CRP microsatellite End-organ dysfunction
 
 
Figure 1.2 Interaction Model of Client Health Behavior with Variables and Model 
Areas Highlighted  
Reprinted with permission. Cox, C.L., Online exclusive: a model of health behavior to 
guide studies of childhood cancer survivors. Oncology Nursing Forum, 2003. 30(5): p. 
E92-9 [35]. 
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sickle cell disease (SCD) and may be useful in determining a severity score. A severity 
score could compliment a physical assessment of underlying secondary complications. 
Healthcare providers could use this information to direct and guide therapeutic decision-
making. This study was a stepping-stone to identification, definition and exploration of 
this genotype and was used to build on a thorough understanding of the dynamic 
relationship between genotype, phenotype and severity of health problems.  
 
 
Definition of Terms 
 
 Theoretical definitions for the major concepts within the conceptual model are 
presented. In addition, because there are a variety of published definitions available for 
the terms used in this study, the following theoretical and operational definitions for the 
variables are provided and used in this study.  
 
  
Elements of Client Singularity and Client Professional Interaction 
 
C-Reactive Protein (CRP): C-reactive protein (CRP) is a genetically controlled and 
highly conserved plasma protein, which participates and is active in the process of 
inflammatory response to any injury or foreign substance. CRP functions by recognizing 
damaged cells and foreign pathogens and initiating an acute phase reaction. This reaction 
has an important role in the innate immunity response the body initiates when invaded by 
pathogenic organisms. This activates the classical complement pathway for the defense 
system against infections and injury and stimulates phagocytosis. 
 
Genotype: The genetic make-up of an organism or groups of organisms with reference to 
a single trait, a set of traits, or an entire complex of traits [38]. Genotype is characterized 
by an individualized genetic code made of base pair nucleotides [38]. It is typically 
studied collectively or with respect to one or a few genes of interest. 
 
Phenotype: The observable and measurable characteristics or properties of an organism. 
These properties are a result of interactions between genes and environment. 
 
Polymerase Chain Reactions (PCR): The process of repeated cycles using DNA to 
denaturation, and renaturation with primer oligonucleotide sequencing in order to grow 
copies of a specific DNA sequence identified by the primers. 
 
Polymorphism: A variation of alleles that is so common that it is found in more than 1% 
of the general population. It may represent a change in the sequence of the DNA affecting 
the functioning expression within the gene or result in the manufacturing of a different 
protein.  
 
Sickle Cell Disease (SCD): SCD is a single gene, autosomal recessive mutation. This 
group of genetic disorders share a common feature: hemoglobin S (HGB S), alone or in 
combination with other abnormal hemoglobin. Within this broad classification of SCD 
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there are numerous genotypes including Hgb SS, Hgb SC, and Hgb β+ and 0 thalassemias. 
The genetic substitution occurs on chromosome 11, in the sixth position and is a 
substitution of valine for glutamic acid [39]. This substitution results in a polymerization 
of the hemoglobin and causes transformation of the erythrocytes. Presence of this 
mutation is determined by electrophoresis. 
 
SNM Severity Score: A Bayesian network model designed by Paola Sabastiani to 
estimate sickle cell disease severity [9]. 
 
 
Elements of Health Outcomes 
 
Cerebral Vascular Accident: Ischemic vaso-occlusion resulting from polymerization of 
the deoxygenated erythrocytes involving medium to large intracranial arteries. Some 
genetic factors may contribute to the phenotypical expression in SCD to this 
complication.  
 
End-stage Organ Disease: Chronic irreversible failure of a specific organ function. This 
damage commonly occurs in the cerebral, renal, pulmonary, and retinal vasculature and is 
related to microvascular injury. These occlusions and damage may remain subliminal 
until an acute response or change in status is observed.  
 
Pulmonary Hypertension: Sustained elevations of pulmonary artery pressure. Measured 
by echocardiogram and identified by Doppler ultrasound of the tricuspid regurgitation. 
Using the velocity of the regurgitation jet across the tricuspid valve a value of greater 
than 2.5 m/sec is considered significant for pulmonary hypertension. 
 
Sickle Cell Nephropathy: A consequence of sickled erythrocytes, resulting in decreased 
medullary blood flow, ischemic microvascular insults and papillary necrosis. Observable 
manifestations are impaired concentrating ability, hematuria, and loss of potassium.   
  
Sickle Cell Retinopathy: Vision loss in patients with SCD. The development is insidious 
and the patients usually are asymptomatic until hemorrhage or retinal detachment occurs. 
Sickle cell retinopathy may differ from diabetic retinopathy due to the increase of 
spontaneous or transient vision loss.  
 
 
Assumptions 
 
1. Phenotype of SCD in adults with SCD cannot be predicted by the hemoglobin 
genotype alone. 
2.   Cumulative organ damage in adults with SCD is a better predictor of early mortality 
than pain episodes. 
3.   Retrospective laboratory levels collected and processed by the study site followed a 
standard operating procedure, and are accurate and reliable. 
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4.   Expression of adhesion molecules in endothelial cells is up-regulated by serum CRP 
levels [40]. 
 
 
Potential Limitations 
 
1. The principal limitation was the interpretation of the results in using a convenience, 
cross-sectional data collection. The causal pathways underlying the variables will not 
be inferred to the relationship of secondary complications and end-stage organ 
damage. 
2. The data collected regarding environmental factors was patient reported and was a 
limitation of this study.  
3. SCD is considered an orphan disease with only approximately 100,000 patients in the 
United States. A power analysis was done to determine group size, but limitations 
exist with the use of a single center for patient recruitment and may have influenced 
the ability to obtain an adequate sample size.  
4.   If patients were not experiencing secondary complications, compliance with routine 
evaluations may not have occurred.  
5.   Processing specimens by a novice bench science researcher may have influenced the 
results. Saliva sampling was collected and stored by protocol and overseen by an NIH 
funded molecular lab with an experienced lab manager. Each sample was split and 
stored for replication submission if needed.  
6.   Genetic evaluation and identification of polymorphisms associated with expression 
levels continues to grow at a phenomenal rate. Results found in the literature have not 
been replicated to provide enough evidence to clearly use the selected microsatellite 
polymorphism as the strongest univariate predictor of risk.   
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CHAPTER 2. REVIEW OF LITERATURE 
 
 
Sickle Cell Disease 
 
 A review of literature relevant to the major concepts proposed in the conceptual 
framework is included in this chapter. The first section addresses SCD pathophysiology, 
prevalence, and risk. End-organ dysfunction associated with SCD is reviewed in section 
two. The final section of this chapter focuses on the role of inflammation, particularly 
CRP, in SCD and end-organ dysfunction and discusses genetic variations in the CRP 
gene.  
 
 
Pathophysiology 
 
 SCD is the most prevalent genetic disease among the African-American 
population affecting approximately 100,000 people in the United States [1, 22]. The 
initial description of SCD was documented by Herrick in 1910 [41]. Sickle cell disease is 
a single gene, autosomal co-dominant mutation. This group of genetic disorders share a 
common feature: hemoglobin S (Hgb S), alone or in combination with other abnormal 
hemoglobin. Within this broad classification of SCD there are numerous genotypes 
including Hgb SS, Hgb SC, and Hgb β + and 0 thalassemia. The molecular basis was 
described in 1957 by Ingram as a genetic substitution for Hgb SS on chromosome 11, in 
the sixth position and is a substitution of valine for glutamic acid [39, 42]. The genetic 
substitution for Hgb SC was first described by Itano in 1950 [6] and was found to be a 
milder form of SCD. This haplotype and the β-thalassemia mutations are associated with 
hemoglobin red blood cell production. All of these substitutions result in a 
polymerization of the hemoglobin and causes transformation of the red blood cells. These 
changes lead to complications related to micro-vascular occlusions and chronic anemia. 
Variability of the expression of this disease is difficult to predict, but if both β-globin 
chains are affected the disease process may be more severe. The severity of the disease 
process and prediction of the phenotype are still unknown [4, 8, 43], and disease 
management creates a  unique challenge.  
 
If oxygen levels drop, morphological changes occur in the erythrocytes as the 
Hgb S molecule polymerizes. The erythrocytes elongate into sickled shapes. The 
erythrocyte becomes fragile and changes shape with each deoxygenation-induced Hgb S 
polymerization. As these deformed cells move through the vascular system, episodic 
vascular occlusions occur. The occlusions interrupt or slow the blood flow causing 
microvascular oxygen deprivation. These occlusions are sporadic and vary in nature and 
intensity by individual patients. 
 
 Some occlusions are clinically undetectable initially but may involve multiple 
organs and tissue. Literature agrees that the red blood cell production for sickled cells is 
initiated by the mutation of the hemoglobin gene on chromosome 11. There remains a 
wide variability of the disease which cannot be fully ascribed to the deoxygenation 
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process of deformity; but the greatest clinical severity has been linked to the highest 
intra-erythrocyte Hgb S levels [6]. The pathogenic mechanism responsible for acute 
painful episodes may not reflect the same pathophysiology of organ damage [6].   
 
 Over the past 25 years, advances in early childhood treatments with prophylaxis 
penicillin have increased the life expectance of adults with SCD well into adulthood [1, 4, 
8, 22, 43, 44]. The evolving clinical course of these adult patients remains associated with 
significant morbidity including leg ulcers, pulmonary hypertension, avascular necrosis, 
renal failure and stroke [5, 43, 45]. According to the US Department of Health and 
Human Services, “health maintenance activities must also address interactions between 
SCD and other common health problems of the adult population” (p. 41), [2]. 
 
 Hydroxyurea is another relatively new environmental factor in the treatment 
regime of SCD. Hydroxyurea is used as an adjunct in the management of SCD to increase 
baseline hemoglobin and reduce painful episodes [39]. Long-term studies are underway 
to help identify the effects of this treatment but results are still pending. The vast majority 
of studies with hydroxyurea are in the Hgb SS population, indicating the Hgb SC 
population will be under represented in research findings. 
 
 
Prevalence, Prediction, and Risk Factors 
  
 Unfortunately the elevated morbidity and early mortality risk remain through 
adulthood, in large part because of the effect of cumulative end-organ damage. Adults 
with SCD have extreme variable phenotypes, which can change through out their 
lifetime. Organ damage begins in childhood [6, 46-49]. There is a strong correlation 
between cumulative organ dysfunction and early mortality in patients with sickle cell 
disease [9, 50-52]. Development of chronic organ dysfunction is a more reliable predictor 
of early mortality than frequency of painful episodes, even though the latter gets more 
attention from patients and their caregivers.  
 
 Any organ with a blood supply is susceptible to damage in patients. However, the 
most common target organs are the brain (cerebral vascular disease, ischemic and 
hemorrhagic stroke), lungs (pulmonary hypertension, restrictive lung disease, possibly, 
reactive airways disease), kidneys (protein-losing nephropathy, focal glomerulosclerosis, 
end-stage renal disease), retina (proliferative retinopathy) and joints (avascular necrosis), 
especially the hip and shoulder joints. The full extent of organ dysfunction in populations 
of patients with SCD is only now being recognized from recent studies of adult 
populations [2, 4, 53-57]. The studies have often identified advanced stages of organ 
damage such as end-stage renal disease, clinically overt stroke, and significant pulmonary 
hypertension. The prevalence of early signs of target organ dysfunction has not been 
widely reported. To make progress in the prevention of chronic organ damage and early 
mortality, better information is needed on the prevalence of early organ dysfunction, 
natural history and pathophysiology of cumulative organ damage.   
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 Healthcare providers have been searching for a prognostic model to account for 
the complex nature of this disease process. A vast majority of the work has been in the 
pediatric setting [50, 58]. In the adult setting several independent risk factors have been 
identified with mortality, such as hemoglobin F% [4, 5], diastolic dysfunction [59], and 
CVA [58, 60]. Predicting the severity of SCD may assist the healthcare provider with a 
more precise prognosis, tailored treatment plans and minimize hazardous interventions. 
Numerous clinical and genetic variants are involved in the severity of SCD. Forecasting 
the severity of the SCD population has proven to be challenging. Models, which predict 
both end-organ dysfunction and mortality risk in adults with SCD, are needed. 
 
 Understanding the relationship between the clinical and genetic variants would be 
helpful in measuring severity of SCD. Sebastiani, et al was the first to attempt to integrate 
13 laboratory tests, 7 clinical events and demographic and treatment information into a 
Bayesian network modeling approach for predicting 5 year mortality [9].  
 
 This Bayesian network model was built on associations of variables and assumes 
“death” was the central component. All other variables stemmed from death. Key clinical 
and laboratory variables were then identified. The study concluded that the 14 variables: 
age, gender, systolic blood pressure, stroke, sepsis, white blood cell count, reticulocyte 
count, pain, priapism, blood transfusion therapy, lactate dehydrogenase (LDH), bilirubin, 
mean corpuscular volume (MCV), and acute chest syndrome were sufficient to predict 
the risk of death [9]. There were ten additional variables in the model that included 
hemoglobin genotype (Hgb SS, SC, Sβ+, or Sβ0), serum hemoglobin levels (Hgb), 
hemoglobin fetal percent (Hgb F%), platelet count, leg ulcers, serum creatinine, 
proteinuria, avascular necrosis (AVN), aspartate aminotransferase (AST), and alanine 
aminotransferase (ALT). The model showed these variables could be discerned by the 
earlier 14 variables    
 
 The use of this model computes a score, which ranges from 0 (least severe) to 1 
(most severe). The authors feel that this score would give an unbiased assessment of 
clinical severity. The initial data source included 3380 adult and pediatric patients from 
the Cooperative Study of Sickle Cell Disease (CSSCD). The average age of this 
population was 20 years. The authors used two unrelated data sets to confirm and validate 
their results [9]. The error rate was 7.5%, suggesting a positive predictive value for the 
severity score in estimating the likelihood of death within 5 years. 
 
 There are several of the limitations of this model. First, genetic polymorphisms 
that could modulate the serum laboratory levels are not included in the model. A second 
consideration is the utility of applying this model to very young patients, who have not 
experienced many episodic vascular occlusions or childhood complications. A final 
consideration is the model may not accurately integrate treatment regimes such as chronic 
blood transfusions and hydroxyurea [9]. 
 
 Sickle cell disease is characterized by micro-vascular occlusions, affecting a 
variety of organs, which may culminate in end-organ dysfunction. Despite advances in 
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treatments, adults with SCD have an elevated morbidity and early mortality risk largely 
because of secondary complications resulting in cumulative end-organ dysfunction.  
 
 
End-Stage Organ Damage 
 
 There is a substantial body of research that documents the variety of end-organ 
dysfunction, which occurs in adults with SCD. This review of literature analyzes three 
organ systems that impact the morbidity and mortality of these patients. The pulmonary 
hypertension, renal and cerebral vascular systems are all effected by micro-vascular 
occlusions related to this hemoglobinopathy. The micro-vascular occlusions have also 
been linked to the inflammatory process. C-reactive protein is a major component of the 
inflammatory complement. The association of serum CRP levels and genetic 
polymorphisms is also evaluated.  
 
 
Pulmonary Hypertension 
 
 Pulmonary hypertension (pulmonary hypertension) is a severe complication and 
end-organ dysfunction in adults with SCD and has been linked to an increase in mortality 
[55, 59, 61, 62]. Reported prevalence of pulmonary hypertension is between 20% and 
35% in adults with SCD [55, 59, 61]. One study reported a median survival rate of 25.6 
months after diagnosis of pulmonary hypertension [54]. The lost of elasticity when the 
red blood cells sickle, results in microvascular occlusions and myocardial cell damage. 
While the exact pathogenesis is multifactorial, the reduced blood flow and the resulting 
ischemia are a major factor in the damage to the myocardium [6, 63]. Low hemoglobin 
levels in most SCD patients are associated with a high cardiac output secondary to an 
increase in the preload and decrease in the afterload, leading to cardiomegaly [6]. In 
patients not afflicted with SCD, but with chronic anemia, low hemoglobin levels are not 
associated with an increase in preload and cardiomegaly [62]. Heart murmurs, possibly 
from increased stroke volumes, have also been documented in SCD patients [62]. One 
study showed that the heart of a typical SCD patient is dilated, with septal hypertrophy 
but normal contractility [62]. 
 
  Factors that may ameliorate the development of pulmonary hypertension are high 
levels of fetal hemoglobin and patients receiving hydroxyurea  [55, 64]. Hydroxyurea 
therapy is attributed to raising fetal hemoglobin levels, and long-term early childhood use 
is being tested to determine if organ damage can be reversed or eliminated [64]. At 
present hydroxyurea is not considered a treatment for pulmonary hypertension. There is 
one study soon to be underway looking at the role hydroxyurea may have in preventing 
and treating PHT [65]. One study found the majority of patients with moderate to severe 
pulmonary hypertension (n = 42) had no correlation to genotype diagnosis of 
hemoglobinapathy sickle cell [61].  
       
 The early symptoms of pulmonary hypertension are nonspecific and the course of 
this complication is gradual. Fatigue, minimal activity, chest pain, and dyspnea can 
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mimic a patient with SCD who does not have pulmonary hypertension [61]. Screening 
may be crucial to a proper diagnosis.  A right ventricular heart catheterization is the 
diagnostic measurement of choice for the most accurate diagnosis, but this invasive test is 
not a suitable screening tool [55]. Echocardiogram is widely used to screen for 
pulmonary hypertension [55, 61, 63]. 
  
 The gold standard for quantifying the degree of heart failure is the ejection 
fraction, usually obtained with an echocardiogram. It has been demonstrated that the 
reading of right ventricular ejection fraction is not an accurate screening measurement of 
dysfunction in the patient with SCD [55] due to the normal contractility of the dilated 
heart muscle. Tricuspid regurgitation jet velocity (TRJV) can be measured with a 
Doppler echocardiogram and has been demonstrated to correlate well with readings 
obtained from cardiac catheterization [55, 66]. A diagnosis of pulmonary hypertension 
using the measurement of TRJV is accepted as the standard [55, 59, 61]. In one study a 
finding of 2.8-3.4 m/sec was used to define mild pulmonary hypertension [67]. The 
accepted diagnosis of pulmonary hypertension in patients with SCD is defined by TRJV 
of > 2.5 m/sec [61, 67]. Analysis of the enlargement of the right ventricle and its 
subsequent dysfunction is controversial. Marchano reported in a sample of adults with 
SCD (n = 141), 18% presented with evidence of diastolic dysfunction but only one-third 
had increases in TRJV [68]. Other measures such as total peripheral vascular resistance 
and heart chamber dilations are being explored to fully evaluate pulmonary hypertension 
[63]. 
 
  Blood transfusions have been used in some patients [6] but the effectiveness 
remains controversial. One study showed some promising results treating pulmonary 
hypertension using oral arginine. In this small study 10 SCD patients were given a 5-day 
course of arginine, and a significant decline in pulmonary artery systolic pressure was 
found [69]. In another larger trial using arginine in children and adults with SCD failed to 
show the arginine had any cellular effect and did not show a reduction of TRJV [70].  
Other treatment options include anticoagulation therapy, prostacyclins, and endothelin 
receptor antagonists, and are treatments options in non-sickle cell disease pulmonary 
hypertension populations [55]. While these treatments are being used in adults with SCD, 
there is little data to support their utility and success.  
 
 
Cerebral Vascular Disease 
 
 Central nervous system (CNS) complications are among the most devastating 
secondary manifestations and have been recognized as key factors of morbidity and 
mortality in SCD. The risk of having a cerebral vascular accident (CVA) is 1 in 10 
children with the hemoglobin genotype of SS [6]. There are several factors that contribute 
to CVA in SCD, and two occurring types: cerebral infarction and intracranial 
hemorrhage. One factor is large vessel lesions that restrict blood flow. Another factor 
involves small vessels and microvascular infarctions occurring from occlusions derived 
from circulation of sickled erythrocytes. A third factor is chronic anemia, which deletes 
cerebral vascular reserves and contributes to the formation of lesions and occlusions [6]. 
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Eighty percent of CVA’s in SCD are infarction, but intracranial hemorrhage can coexist 
in the damaged area. Intracranial hemorrhage may be the result of aneurysms promoted 
by lesion formation. Intracranial hemorrhage is thought to be more prevalent in young 
adults. The average age of persons experiencing intracranial hemorrhage is 24 years [71]. 
CVA from infarction has been described in children prior to age 20 years [60].   
  
 CVA in SCD was first described in 1923 by Syndenstricker [6], using the 
neurologic exam as the basis of diagnosis with clinical manifestations of hemiparesis, 
facial asymmetry, and aphasia, with or without diminished mental capacity [72]. By the 
early 1970s cerebral arteriograms were reporting evidence of stenosis or occlusions of the 
distal internal carotid arteries or the proximal portions of the anterior cerebral arteries 
[73, 74]. During the 1990’s magnetic resonance imaging (MRI) and magnetic resonance 
angiography (MRA) testing revealed additional information on the extent and location of 
cerebral damage. The concept of silent cerebral infarcts was introduced and more 
screening for damage was initiated in children [58, 75]. 
 
 Patients with overt CVA have a 46% to 90% risk of recurrent CVA [6] and 
intervention therapy of chronic transfusion has been a widespread practice since the 
1970’s [76, 77]. The length of time transfusion therapy is used is under considerable 
question and many adult patients remain on this therapy. No clear guidelines for 
discontinuation have been established [78]. Chronic transfusion therapy is associated 
with significant risk of iron overload and alloimmunization. Anticoagulation therapy is 
not advised, due to the increased risk of intracranial hemorrhage in the patient with SCD.        
 
 
SCD Nephropathy 
 
 The kidney is a major target for functional and structural damage for patients with 
SCD [53, 79, 80]. The kidney is affected along the length of the nephron from the 
glomerulus to the papillary tip. SCD alters the glomerular structure and function by 
allowing free filtration of H2O and small molecules but retards the filtration of proteins. 
Because of the microvascularity of the kidney is sensitive to hypoxia from sickled 
erythrocytes. There is an increase in oxygen consumption that may be induced by an 
increase in metabolic activity. SCD causes a sclerosing process leading to glomerular 
enlargement, identified as glomerulosclerosis [6]. Enlargement is most likely due to 
increased glomerular filtration rate (GFR). Changes in oxygen delivery from ischemic 
reperfusion injury also contribute to the physiological disturbances especially in the 
blood flow to the distal nephron and medullary [81]. Three major abnormalities have 
been identified in patients with SCD: 1) the decreased ability to concentrate urine, 2) 
incomplete formation of the distal renal tubule leads to increased acidosis, and 3) 
impaired potassium metabolism [6, 56, 81]. Kidney function is also complicated by 
cardiac-output.  
  
 The ability to concentrate urine is dependent on the structural integrity of the 
loops of Henle. In patients with SCD, the defect is a result of the loss of deep 
juxtamedullary nephrons. The outer medulla remains unaffected, therefore under baseline 
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stable conditions the concentration ability is not affected [6]. When there is any volume 
loss or episodes of dehydration the condition is exacerbated. It is suspected this 
abnormality occurs at an early pediatric age [53, 56, 81]. 
 
In urinary acidification, the severity of the defect is directly related to the extent 
of the concentration defect. It occurs as a combination of events, primarily through the 
incomplete form of the distal tubule [6].   
 
Potassium excretion by the kidneys is regulated by the action of aldosterone upon 
the distal tubule. Renal insufficiency is difficult to detect until progressive injury has 
occurred and serum indicators of nephropathy differ in patients with SCD. Treatment 
options using an ACE inhibitor may exacerbate hyperkalemia in patients with SCD, the 
hyperkalemia leads to an overestimation of GFR, when measuring normal serum 
creatinine levels [6]. Inaccurate GFR results make it imperative to healthcare providers to 
request patients complete a 24° urinalysis. A 24° urinalysis is the gold standard of kidney 
function and an accurate estimation of kidney function. Function can be measured but 
testing is not without problems [82]. It is difficult for patients to capture all of the urine in 
the designated time period, and to return the urine immediately to the lab for analysis. 
Transportation to and from the laboratory can be challenging and expensive for many 
adults with SCD and is an additional burden of chronic illness management. 
 
The traditional definition of normal serum creatinine levels higher than 1.49 
mg/dL (> 132 µmol/L), seriously underestimates the frequency and severity of renal 
impairment in patients with SCD (Hgb SS) [80]. There is currently no accepted definition 
of adjusted serum creatinine levels for SCD patients.  
 
Inflammation and abnormal adhesion of sickled cells are thought to contribute to 
vascular occlusions that lead to chronic end-organ dysfunction [5, 10, 21, 24]. CRP 
induced inflammation is an acute phase response to vascular damage. Serum CRP levels 
are a newly recognized serum biomarker for vascular damage [25, 26, 83] but little 
literature addresses the utilization of CRP levels in assessing potential end-organ 
dysfunction in adults with SCD [21]. 
 
 
C-Reactive Protein 
 
C-reactive protein (CRP) is a genetically controlled and highly conserved plasma 
protein, that participates and is active in the process of inflammatory response to any 
injury or foreign substance [40]. CRP functions by recognizing damaged cells and 
foreign pathogens and initiating an acute phase reaction. This reaction has an important 
role in the innate immunity response the body initiates when invaded by pathogenic 
organisms. CRP activates the classical complement pathway for the defense system 
against infections and injury and stimulates phagocytosis [40]. Tillett and Francis, first 
described this plasma protein in the 1930’s as a marker for pneumococcal infections [84].  
Advances in the testing procedures and measuring of the CRP levels have found a link 
between CRP levels and low-grade chronic inflammatory responses that may point to the 
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development of Metabolic Syndrome (Met-S), and cardiovascular disease (CVD). The 
purpose of this discussion is to define the serum and genetic characteristics of CRP and 
its relationship to Met-S, CVD, and sickle cell disease (SCD). 
  
Plasma CRP levels fluctuate in response to acute inflammation. Inflammation is 
an immune response; it can be initiated by injury, infection or possibly by genetic 
predisposition. In healthy adults in a steady state, the plasma concentrations are in the 
range of 0.1 to 10 mg/L [14]. Traditional CRP has been used primarily as a marker of 
inflammation. There can be a 1000 X rise in plasma concentration levels following tissue 
damage or inflammation [14, 40].  Plasma protein levels have been used to determine 
disease progress or the effectiveness of treatments for many years. The specificity of the 
CRP test is general, only establishing the presence of inflammation and response to 
treatment. Secondary elevations in the plasma levels have been identified with 
inflammatory diseases, such as rheumatoid arthritis, autoimmune diseases, and 
inflammatory bowel disease. In the 1990’s a direct correlation between unstable angina 
and elevated plasma CRP levels was described [85-87]. CRP plasma protein is produced 
in the liver and smooth muscle cells of the coronary arteries [40, 88].  
 
The CRP molecule structure consists of five identical noncovalent protomors 
clustered around a central core [40]. The surface contains binding sites and receptors that 
interact in the function of the molecule. There are critical interactions in a number of 
bacterial species but the configuration of the molecule makes circulating CRP 
inaccessible to normal cells. The CRP molecule can only bind to bacterial molecules in 
damaged and apoptotic cells [40, 88].  
 
 There are five essential functions of the CRP molecule. The first CRP function is 
to recognize and identify pathogens in the blood. When increased pathogens are 
recognized the release of increased levels of CRP is initiated. The second follows the first 
and is activation of the complement system. The complement system consists of 30 
proteins that play an important role in body defense mechanisms that fight infection. 
 
The third CRP function is to enhance phagocytosis. The most important facet of 
phagocytosis is its control of inflammation. Depending on the phagocytosed particle, 
phagocytosis can induce inflammation or, as in the case with apoptotic cells, induce 
resolution of inflammation. Phagocytosis is also involved in immune tolerance that 
prevents inflammation against normal components of the body. 
 
The fourth CRP function is to up-regulate the expression of adhesion molecules in 
endothelial cells. The fifth function of CRP is to inhibit endothelial nitric-oxide synthesis 
[40].  The CRP abilities to up regulate the expression of adhesion molecules in 
endothelial cells and to inhibit endothelial nitric-oxide synthesis are essential. Endothelial 
nitric-oxide generates nitric-oxide in blood vessels to regulate vascular function.  
 
Approximately two-thirds of the American population have a plasma CRP level 
under 3 mg/L [85]. A serum CRP level > 10 mg/L has been considered abnormal. 
Traditionally, higher normal circulating CRP levels, greater than 3 but less than or equal 
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to 10 mg/L, have been historically regarded as clinically insignificant. The estimated time 
to complete a plasma CRP level test is approximately 5 minutes. Test results can be 
reported in approximately 4 hours. Progressive increases in CRP levels correlate with 
increases of inflammatory injury. CRP levels may be used to follow therapeutic response 
medications. A higher sensitivity CRP level test (hs-CRP) has been developed. This is an 
automated blood test designed for greater accuracy in measuring chronic slight increases 
in CRP levels. 
 
In the past 5 years there has been increasing evidence of the usefulness of CRP 
testing and research related to CRP levels. Research has been expanding in two areas. 
The first is using serum CRP levels as biomarkers and explaining the relationship of 
numerous disease processes to elevated CRP levels. The second is the emerging genetic 
characteristics and information that are being generated by the CRP gene. This 
information specifically looks at the CRP function and expression of the plasma protein 
in circulating blood. Nurses must be informed and knowledgeable regarding the advances 
involving this inflammatory biomarker.  
 
 
Atherosclerosis 
 
Inflammation characterizes the process of atherosclerosis, and atherosclerotic 
plaque may be an important source of systemic markers of inflammation [89]. Increasing 
inflammation is associated with clinically instability of atherosclerosis [89]. Questions 
arise regarding the reliability of novel biomarkers to provide reliable, accurate, and cost-
effective information and their ability to predict future events. 
 
CRP is present in atherosclerotic plaques and has been associated with plaque 
instability and thrombosis [15]. It is possible, through an effect on acute phase response, 
CRP genotype is more strongly associated with more severe events [15]. It was first 
reported in 1990 that CRP levels were elevated in patients with unstable angina [87]. 
Another landmark study demonstrated elevated CRP levels were useful in predicting the 
long term outcomes of unstable angina patients [86]. It was reported in a 1997 study, that 
CRP levels were elevated for many years prior to a myocardial infarction or CVA [90]. 
Study participants were men with increased CRP levels and the results showed a 3-fold 
increase in risk for myocardial infarction (MI) and a two-fold increase in risk for stroke. 
This study increases the probability of predicting risk of MI as many as 8-years in 
advance [90]. 
 
The CRP biologic marker of interest was also key in several prospective nested 
case-control studies, that were associated with increase risk of MI, stroke, sudden cardiac 
death, and peripheral arterial disease [91]. CRP was found to be a strong predictor of 
future cardiovascular risk, and reported some clinical value with the treatments of statin 
therapy for primary prevention among persons with elevated CRP but low LDH levels 
[91]. A more sensitive measure of low serum levels of CRP is the hs-CRP test; several 
studies employ this measure to gauge inflammation. 
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The Women’s Health Study (WHS) conducted several important follow-up 
studies using CRP values. Results found that hs-CRP is associated more closely with 
ischemic stroke than CVD and that concomitant evaluation of lipid levels and hs-CRP 
may improve risk assessment [92]. Another analysis of the same cohort found that hs-
CRP added prognostic information beyond what was conveyed by all lipid measures [93].  
 
Cardiovascular guidelines stress the importance of identifying individuals with 
Metabolic Syndrome (Met-S). These individuals are a high risk group for cardiovascular 
events [94]. WHS cohort showed CRP levels to be strong predictors of MI, stroke, and 
incidence of type 2 diabetes [94]. CRP is a marker for innate immunity and elevated CRP 
levels directly effect vessel walls [94]. Insulin resistance and atherosclerosis share a 
common inflammatory basis. Smoking and aspirin may affect CRP levels. Statin-class 
medications are relatively more effective in reducing vascular risk among those with 
elevated CRP levels. The WHS cohort study also showed that rosiglitazone directly 
reduced CRP levels. It is possible to speculate that CRP may potentially play a more 
direct role in promoting hypertension [25] and opening possible treatment options for 
chronic elevations in CRP levels. Recent data suggests CRP concentrations known to 
predict CV events directly squelch the production of nitric oxide by endothelial cells, 
possibly leading to disturbance of vasomotor tone and unopposed vasoconstriction [25]. 
 
 
Metabolic Syndrome 
 
To fully evaluate the clinical usefulness of CRP as a new biomarker requires more 
direct comparison with Met-S biomarkers, either in combination with or in place of more 
traditional markers. In a secondary analysis from the National Health and Nutrition 
Examination Survey, the mean and median levels of CRP were higher in subjects with 
components of Met-S as defined by the Adult 3rd Report of the National Cholesterol 
Education Program Expert Panel on detection, evaluation and treatment of 5 components 
of Met-S [95]. This study included a large percentage of children and adolescents. In a 
prospective study of CRP and its relationship to diabetes and Met-S, CRP correlated with 
all metabolic indexes in women. CRP had a predictive value in Mexican women 
especially in the development of Met-S independent of adiposity and glucose but risk was 
not evident in men [96].  
 
A study by Ridker, et al, showed interactions between biological markers and 
more traditional risk factors, such as blood pressure, smoking, obesity, diabetes, 
decreased physical activity, and the use of hormone replacement therapy [94]. In an 8-
year follow-up cross sectional study using baseline CRP levels and excluding hormone 
replacement therapy, CRP levels were found to add important and independent 
prognostic information in terms of cardiovascular risk [94]. In another secondary analysis 
of the WHS using self-reported blood pressure levels, the joint effects of the relative risk 
of future cardiovascular events were analyzed using CRP and blood pressure. All were 
found to be independent determinants of cardiovascular risk and their predictive value 
was additive [25]. 
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Blake, et al found in a secondary analysis with CRP and blood pressure that these 
were determinants of cardiovascular risk and both added predictive value [25]. The 
Women’s Health Study conducted several important follow-up studies using CRP values. 
Conclusions were that hs-CRP is associated more closely with ischemic stroke than 
cardiovascular heart disease (CHD) and that concomitant evaluation of lipid levels and 
hs-CRP may improve risk assessment [92]. In another analysis of the same cohort 
conclusions were that hs-CRP added prognostic information beyond what was conveyed 
by all lipid measures [93]. Using a high risk cohort, Beckman et al found an increased 
CRP was associated with peripheral arterial disease using hard events (myocardial 
infraction, stroke and death) for follow-up [89]. 
 
The plasma CRP biomarker is likely to have an important role in establishing risk 
stratification of patients with Met-S and scoring risk for long-term implications of 
cardiovascular disease. This test has the advantage of being relatively risk-free, 
inexpensive and applicable to a wide range of populations at risk for Met-S. The hs-CRP 
test can be completed in a clinical outpatient setting. Immediate follow-up discussion, 
explanation of testing results and prevention interventions can be initiated. Because it is a 
diffuse test, the tissue or organ etiology may not be determined. It is still necessary that 
healthcare providers capture a thorough history, ongoing assessment, and complete 
testing for optimum continuity of care for patients at risk. The primary goal of risk 
prediction is to identify high-risk patients so prevention measures can be initiated to 
improve health outcomes. 
 
 
Sickle Cell Disease 
 
In a review of selected literature, Albert, et al reported on the traditional CVD risk 
factors and African Americans. It was found that: 1) hypertension and left ventricular 
hypertrophy leads to an increase of out-of-hospital sudden deaths, 2) African Americans 
traditionally experience lower rates of coronary artery disease but an increase in 
morbidity of cardiovascular disease, 3) Met-S and obesity lead to congestive heart failure 
and sudden death, and 4) novel cardiovascular risk factors: CRP levels and Lp(a) levels 
are higher in African Americans. This evidence indicates a need to evaluate non-
traditional biomarkers that may be associated with Met-S and CVD. Atherosclerosis 
would not be an issue in this ethnic population. It is unclear in the literature if any of 
these traditional CVD risk factors have been studied in the SCD population. 
 
 Biomarkers are blood plasma laboratory measurements of molecules, proteins or 
enzymes, which give independent prognostic or diagnostic value by highlighting an 
underlying disease process [26]. This may highlight a disease process such as sickle cell 
disease (SCD) or its sequelae such as pain episodes, secondary complications, or 
cardiovascular complications of SCD in adults. Additional biomarkers are needed to fully 
investigate the incidence of Met-S in this specific population. The testing must also be 
minimally invasively for best compliance with any population of patients. Levels of CRP 
in all SCD patients have not been extensively studied. Most efforts have involved 
pediatric age groups. A small study by Hibbert, et al showed CRP moderately increased 
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in stable symptom-free patients and significantly increased during painful vaso-occlusive 
crisis in children with SCD. Regression analysis of this small study (n=12) of children 
with SCD), demonstrated CRP was a predictor of corrected resting energy expenditure 
and fat mass in this population [97].  
 
In a retrospective study, Schnog, et al reviewed CRP levels. The study was 
contrasting 3 groups. Group 1 was Hgb SS patients, group 2 was Hgb SC patients, and 
group 3 was matched African American blood bank donors. The results found elevated 
levels of CRP as a general marker of inflammation in all groups. No detection of 
significant correlation of hs-CRP levels was made to clinical events. A significant 
relationship was found in group 2, Hgb SC between free and total protein S and hs-CRP 
[24].  
 
 
Genetic Evaluation 
  
Genetic factors account for a 35-40% variance of CRP levels demonstrated by 
family and twin studies [13, 98]. Several common polymorphisms have been identified 
with altered plasma CRP levels [98]. The CRP gene lies on chromosome 1q23 and is 
composed of 2 exons and an intron. Numerous polymorphisms have been reported but 
none are known to change nonsynonymous amino acid production. The polymorphisms 
are the only genetic markers with potentially high linkage disequilibrium with causative 
genetic markers [13]. In a more in-depth analysis of the CRP gene, Crawford, et al re-
sequenced 1000 chromosomes, his research demonstrated that the CRP gene is ideal for 
deep and medical re-sequencing because it is a small gene at ∼2kb [99]. From his 
research it is suggested that it may be more efficient to re-sequence individuals at 
extreme low/high end of distribution in search of rare single-nucleotide polymorphism’s 
(SNP) that impact phenotype. Re-sequenced genes for the purpose of cataloguing both 
common and rare variations may be used in common disease/common variant study 
designs using a tag SNP approach. Application of this approach can then be applied to 
several population studies with very few population specific modifications [99]. 
 
Dupuis, et al in 2005 attempted to describe inter-individual variability in systemic 
inflammatory biomarkers using banked DNA from the Framingham Heart Study. 
Multiple genes on chromosome 1 were found to influence inflammatory serum levels 
[27]. Using this same-banked DNA, Kathiresan, et al investigated the influence of genetic 
variation of the CRP gene on CRP blood levels. Thirteen SNP’s were genotyped with 
measured CRP levels. Clinical variables explained 26% of inter-individual variation in 
CRP [100]. Two novel common SNP’s in the promoter region of the CRP gene were 
identified and associated with plasma concentration of CRP by Kovacs, et al located at 
position –286 with C>T>A and –717 in relation to the transcriptional start site. Strength 
of the data did not support functionality of the variants [18]. The major limitation from 
these studies was the use of an all white cohort, opening the question of variation among 
other ethnic cohorts. 
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In a large genetic study using the NHANES III banked DNA, 4 haplotypes had 
significant association with CRP levels. It was demonstrated that specific CRP SNP’s and 
haplotypes are associated with serum CRP levels in the general population [101]. 
Heritability estimates were approximately 20-60% of the variance of baseline CRP. This 
evidence supports that CRP levels are attributed to basic genetics. In a 2003 study using 
male army recruits and patients receiving a coronary artery bypass graft (CABG), 2 novel 
polymorphisms were identified in the CRP gene. At location +1444 a C>T variant had a 
strong independent association influencing basal and stimulated CRP levels. This variant 
has preliminary support as a functional candidate SNP [14]. 
  
Suk, et al did an assessment of 2 SNPs in the CRP gene; exon 1059 G>C and 
intron T>A as a base substitution. These genetic polymorphisms were significantly 
associated with baseline CRP levels even after adjustment for environmental variables. 
This provided evidence of genetic components of CRP levels, independent of traditional 
risk factors for CV disease [13]. 
  
In an attempt to show an association of polymorphisms in the CRP gene with 
CRP serum levels and cardiovascular events, Lange, et al found no association between 
carotid intima-media thickness and cardiovascular events. This prospective trial involved 
4 tag SNPs genotyped in 3941 white participants, and 5 tag SNPs in 700 black (African-
American) participants. The study reported an association of SNP 790T with low CRP 
levels in the black population. It was also shown that homozygosity for the 790T allele 
was associated with a 4 fold increase risk for acute myocardial infarction [15]. 
 
Minor alleles of 4 SNPs are consistently associated with a functional role in 
serum CRP levels in three major cohorts, reported by Miller, et al [16]. A secondary 
analysis and re-sequencing was undertaken with the WHS, the Pravastatin inflammation 
CRP evaluation trial and the Physician’s Health Study. The functional role for 5’ SNP –
286 C>T>A and 3’ –UTR SNP and 1846 G>A did not associate with an increased risk of 
MI but implied that both genetic and environmental factors contribute to increased CRP 
levels [16]. 
  
Following Miller’s lead, DNA samples were analyzed for seven common 
significant SNPs. It was found that minor alleles 1, 3, 4, and 6 were associated with high 
medium CRP levels. Alleles 5 and 7 were associated with low CRP values and 2 had no 
effect [98]. These results may be important in the study of future populations when 
attempting to characterize phenotypes. An allele associated with higher CRP levels would 
confer an increased risk of CVD [15]. Results suggest a genetic basis may underlie, in 
part, the relationship between CRP concentration and CVD risk in older adults [15]. In a 
smaller black cohort, specific CVD outcomes associated with CRP genotypes differed by 
ethnicity [15] and could be explained by allele frequencies. This study has the limitation 
of a smaller AA sample size (n = 700) vs. the Caucasian sample size (n = 3941) [15]. 
 
Strong evidence supports hs-CRP as an independent predictor of coronary artery 
disease and is directly causally uncertain. Assessment of risk factors provides guidance 
for clinical management. Clinical combination of hs-CRP, tropin, and b-type naturetic 
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peptide has been advocated as a means of risk stratification [26]. One study using 
multiple cohorts indicated hs-CRP provided additive risk information across all levels of 
the Met-S [26], but few studies have explored populations outside of CVD. 
 
Szalai, et al., has been working with an inflammatory disease populations 
unrelated to CVD, 244 cases of systemic lupus etythematosus (SLE) were used in this 
study (n = 546) [12] and more recently with this same cohort looking for vascular arterial 
events such as arterial claudication and arterial thrombosis [102]. The study identified 
thirteen alleles of the microsatellite (CA)n in the intron of the CRP gene. Microsatellites 
are a simple sequence repeat, found in the nuclear DNA and generally a base pair 
combination-repeating unit. DNA structure is affected by base paired Cytosine (C) and 
Adenine (A) or CA repeats within the structure of the gene [12]. An example of a 
common microsatellite is a CA repeat. A CA repeat is frequently found in human DNA 
and other genomes and can have hundreds of consecutive repeats. Seventy-five percent of 
these repeats are found in the intergenic noncoding regions [103]. There are often many 
alleles present in a microsatellite locus, and have become powerful tools in population 
genetic studies, recombination mapping and providing support for specific alleles that are 
closely related [12, 104].  
 
Nine to twenty-five repeats were counted and 75% of the subjects had (CA)16 and 
(CA)25 repeats. The controls used in this study were divided by Caucasian and African 
American (AA) ethnicity. A higher frequency of intermediate repeat alleles (CA17-CA25) 
arose from the AA linage. Other results from this study were association of different CRP 
alleles with differences in baseline CRP serum levels. Even with considerable variability 
in CRP expression of SLE patients, results strongly suggest a genetic component to 
baseline CRP levels [12]. Investigation continues to determine the mechanisms involved 
between the microsatellite (CA)n CRP polymorphism and CRP expression. Szalai’s study 
was one of the first to use a subject pool with an inflammatory disease process, other than 
atherosclerosis. The growing evidence from this study makes this polymorphism clearly 
worth investigating.  
 
 
Risk Factor 
 
Stampfer, Ridker, and Dzau distinguished between causal risk factors that directly 
reflect underlying biology of disease and risk factors used solely for prediction [105]. A 
goal of identification of more predictive risk factors is to identify individuals who are 
more likely to develop the disease or secondary complications from a disease and target 
them for more intensive intervention. A predictive risk factor must be present and 
measurable before the clinical appearance of the outcome. Risk factors are independent 
predictors and improve the predictive power of other risk factors already identified. Risk 
factors may vary depending on the characteristic of the population. 
 
 Little work has been done in the area of genetic CRP polymorphisms in a sickle 
cell disease (SCD) population. It is consistently difficult to characterize the phenotype of 
patients with this disease process. As vast amounts of new data are being generated, the 
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nursing implications regarding CRP levels and the interpretation of plasma and genetic 
results will be a challenge for patient teaching. There is enough evidence to support CRP 
as a viable biomarker of severity. Further exploration will be needed to assess the 
importance and independent prognostic value of genetic and environmental factors for 
future events. Replication of genetic studies supporting genetic CRP variants, which link 
elevated levels to genetic variants, will be another step toward individualized medicine 
and evaluation of risk factors. It has yet to be determined if CRP levels and genetic 
polymorphisms in the CRP gene will be useful tools in the SCD population. 
 
 
Summary of the Review of Literature 
 
 Sickle cell disease is a genetic hemoglobinapathy characterized by micro-vascular 
occlusions. A multitude of secondary complications can arise from these occlusions. 
Three of the most severe complications are pulmonary hypertension, renal end-organ 
dysfunction and cerebral vascular accidents. Finding effective methods to evaluate the 
severity of these complications has been a challenge. One proposed method is to develop 
a severity score that would help predict both end-organ dysfunction and mortality risk in 
adults with SCD.  
 
 Another proposed method of evaluating complications would be the use of serum 
and genetic biomarkers. SCD exhibits an unusual inflammatory profile. Research 
evidence demonstrates that inflammation may be a factor in the pathogenesis of vascular 
injury related to secondary complications. CRP has been targeted as a factor that might 
be promising as a serum and genetic biomarker for secondary complications in adults 
with SCD.     
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CHAPTER 3. METHODS 
 
 
 This chapter provides a detailed description of the study design, sample, setting, 
and the instruments. Procedures for data collection and statistical analyses as well as 
protection of human subjects are discussed. 
 
 
Material and Methods  
 
 
Research Design and Study Population 
 
 In this descriptive, cross-sectional, convenience sample study, 29 patients with 
SCD were divided into two groups by clinical evidence of secondary complications, mild 
and severe. The severe group was further divided into three groups based on the type of 
secondary complication. The three groups were pulmonary hypertension, renal end-stage 
organ dysfunction, and cerebral vascular accident (CVA), see Figure 3.1.  
 
 The renal group exhibited clinical evidence of end-stage renal dysfunction with a 
glomerular filtration rate (GFR) ≤ 60% or a 24° urine protein level ≥ 500 mg/24°. The 
pulmonary hypertension group exhibited clinical evidence with a tricuspid regurgitation 
jet velocity (TRJV) ≥ 2.5 m/s. The third severe group was clinical evidence of a CVA by 
historical documentation or magnetic resonance imaging (MRI) and magnetic resonance 
angiography (MRA).   
 
  This was a prospective single visit study. All patients had a diagnosis of Hgb SS, 
SC, Sβ+, or Sβ0. The patients were screened and approached during scheduled routine 
clinic visits. Recruitment was from February 2008 to July 2008.  
 
 A total of 81 patients from the adult hematology/oncology clinic had a complete 
secondary complication evaluation. Patients were evaluated by the physician co-
investigator and the investigator. All patients who meet inclusion criteria were invited to 
participate. All subjects were 18 years of age or greater. Representative age samples of 
adults with SCD are typically between 18-59 years. To assess the feasibility of the study 
a retrospective chart review was completed in April 2007 at the University of Tennessee 
Cancer Institute.   
 
 
Projected Sample Availability 
 
 There is clear evidence that patients with SCD develop secondary complications 
that lead to end-stage organ damage and increased mortality rates. The projected sample 
availability was obtained from a retrospective chart review completed in the spring of 
2007 at the University of Tennessee Cancer Institute. This study briefly highlighted the 
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Mild (n = 8) Severe (n = 21)
Renal (n = 6)     Pulmonary (n = 9)     CVA (n = 6)     
Sickle Cell Disease Subject (n = 29)
 
Figure 3.1 Study Design 
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common secondary complication of SCD. Morbid and potentially lethal organ injuries 
were very common in the adults with SCD. Additional work was necessary; using a 
regional population for a prospective study that would contribute to the understanding of 
severity in SCD. 
 
 
Sample and Setting 
  
A convenience sample was obtained from Hgb SS, SC, Sβ+, and Sβ0 patients who 
received care at the University of Tennessee Cancer Institute between February 2008 and 
July 2008. Data collection occurred at two locations of the University of Tennessee 
Cancer Institute, Medical Center and DeSoto Center. The patients were identified at 
follow-up routine hematological management of the underlying disease process and 
recruited by the investigator. Subjects were screened for potential participation in the 
study after chart review and consultation with the physician co-investigator, who 
clinically manages the patients.  
 
 Children under the age of 18 presented a complex set of medical and social issues 
that challenge the clinician and are under the care of pediatric hematologists outside of 
the study site, so children under the age of 18 were excluded. The pediatric caregivers 
treating the children with SCD transition the patients at age 18 years into the adult care 
setting. Thus, patients who were 18 years and older, and under the care of University of 
Tennessee Cancer Institute, were included in the identification and recruitment. A 
detailed description of the sample is provided in chapter 4. 
 
 
Inclusion Criteria 
 
• Adults who previously had received a diagnosis of SCD with historical 
confirmatory electrophoresis of SCD including hemoglobin patterns (SS, SC, Sβ+, 
or Sβ0) were eligible. 
• Participants had to be age 18 years to 65 years. 
• All participants had to be able to provide informed consent. 
• Stratifying criteria was then used for group placement. 
 
Group I Mild: The subjects had to meet all areas to be included into this group. 
 
• Negative history of ACS or pneumonia 
• Negative history of priapism 
• Negative history of leg ulcers 
• Negative history of clinical stroke 
• Tricuspid Regurgitation Jet Velocity < 2.5 m/s 
• Glomerular Filtration Rate > 90 % 
• 24º Urine protein < 200 mg 
 
29 
 
Group II Severe: 
 
• Major severity--One system of the following had to be verified to be included into 
this group: pulmonary jet velocity from historical echocardiogram of ≥ 2.5 m/s, or 
glomerular filtration rate (GFR) ≤ 60%, or 24º Urine protein ≥ 500 mg, or clinical 
stroke by historical documentation or MRI. 
• Minor-Multi-system severity--If subject did not meet the single organ criteria of 
severity, the inclusion for multi-system severity was defined as: GFR ≥ 59 but ≤ 
90 % + 24º Urine protein > 200 < 500mg + MRI abnormalities suggesting silent 
cerebral ischemia or documentation of AVN or MRI abnormalities suggesting 
silent cerebral ischemia + 24º proteinura > 200 but < 500mg + retinopathy by 
historical exam or documentation of AVN. 
 
 
Exclusion Criteria 
 
• Presence of acute significant health problems requiring imminent hospitalization 
(i.e. severe cardiomyopathies, Hepatitis B, Hepatitis C, HIV, SCD renal failure) 
• Pregnancy-determined by self report 
• Acute active pain episode at blood draw 
• Signs or symptoms of active infection (i.e. fever, chills, acute pain, nausea or 
vomiting) 
 
 
Instrumentation 
  
 Each subject provided written informed consent. Consent was obtained at the 
clinic visit, after determination that all inclusion and exclusion criteria had been met. 
Demographic information such as date of birth, race, height, weight, gender, clinic 
location and clinical information such as history of surgical cholecystectomy, surgical 
splenectomy, leg ulcers, historical CVA, ACS, retinopathy, and priapism was obtained 
from the subject’s medical records to characterize and describe the sample. These 
variables were also used in the calculation of the SNM Severity Score. 
 
 
Samples Collection and Settings 
 
 All samples were collected at the University of Tennessee Cancer Institute at two 
locations, Medical Center and DeSoto Center. Each patient had blood drawn for routine 
laboratory testing which occurs at each visit. Venous blood samples were processed in 
according to regulations from the certified Clinical Laboratory Improvement Amendment 
(CLIA) clinical laboratory at the study setting clinic using standard procedures. This 
laboratory testing was not considered part of the research protocol. Standard visit 
laboratory tests are complete blood counts (CBC), chemistry panel, hemoglobin 
electrophoresis, B-type naturiuretic peptide (BNP) CRP, and lactate dehydrogenase 
(LDH). Tests included in a CBC were: white blood cell count (WBC), red blood cell 
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count (RBC), hemoglobin level (Hgb), hematocrit (Hct), platelets, mean corpuscular 
volume (MCV), mean corpuscular hemoglobin (MCH) and WBC differential. Test 
included in a Chemistry panel were serum levels of: albumin, alkaline phosphatase 
(ALP), alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total 
bilirubin, blood urea nitrogen (BUN), calcium, chloride, creatinine, glucose, potassium, 
total protein, and sodium. 
 
Samples were collected during the routine clinic follow-up appointment using the 
Oragene ™/saliva collection kits, which contain a proprietary solution to immediately 
stabilize the DNA. The primary investigator collected all DNA samples by having the 
subjects spit into coded sample containers. The samples were then de-identified with 
subject numbers. Risks associated with saliva sampling were transient dry mouth. When 
the lid is closed after sample collection the proprietary solution immediately mixes into 
the sample. 
 
 
Manual Purification of DNA Protocol 
 
 DNA in Oragene sample kit is stable at room temperature. All samples were taken 
to Dr. Ron Adkins microbiology lab, located in the Children’s Research area of Le 
Bonheur Children’s Hospital, Memphis, TN within 48 hours of collection. The 
purification process started with each sample incubated at 50º C in a water incubator for a 
minimum of 1 hour. The Oragene/saliva sample was then placed in clean 1.5 mL 
microcentrifuge tubes by dividing the sample into five, 500µL aliquots. All remaining 
samples were frozen in a -20º C freezer. 20µL of Oragene Purifier (OG-L2P, supplied by 
the manufacturer, Gentek, Ottawa, Ontario, Canada) was then added to each 
microcentrifuge tube and mixed by vortexing for a few seconds. Each sample was 
incubated on ice for 10 minutes and then Centrifuge at room temperature for 15 minutes 
at 13,000 rpm (15,000 x g). The clear supernatant was then transferred into a fresh 
microcentrifuge tube. The impurities pellet was discarded. 500µL of room temperature 
95-100% ethanol was added to each 500µL of supernatant. All tubes were mixed gently 
by inversion 10 times and allowed to sit at room temperature for 10 minutes. Each tube 
was then centrifuged at room temperature for 2 minutes at 13,000 rpm (15,000 x g). All 
pellets were carefully dislodged and collected into one of the microcentrifuge tubes. This 
single tube with the 5 pellets was centrifuged at room temperature for 2 minutes at 13,000 
rpm (15,000 x g). The supernatant was carefully poured off and discarded. The pellet was 
allowed to air dry. 250µL of 70% ethanol at room temperature was added and allowed to 
sit for one minute to remove residual inhibitors. The ethanol was then gently poured off; 
care was taken to not disturb the pellet. 100µL of DNA buffer (1:10 TE) was added to 
DNA pellet and vortexed for 5 seconds to re-hydrate pellet. The sample was then 
incubated at room temperature for 24 hours. All samples were then maintained, when 
fully hydrated, at -20º C for long-term storage. 
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Measurement of Quality and Quantity of DNA 
 
 For efficient use of DNA samples in sequence analysis, accuracy, and precision of 
the DNA concentration are critical. The OD method of DNA quantification has been 
found to be the most accurate method of measurement [106]. Purity was determined by 
calculating the ratio of absorbance at 260 mm to absorbance at 280mm. Pure DNA has a 
A260/280 ratio of 1.7 to 1.9. The concentration of the DNA samples was determined by 
calculating OD 260/280 readings from a dual beam Beckman DU-600 spectrophotometer 
(Beckman Coulter, Inc., Fullerton, CA).  
 
 
Primer Design 
 
 Ensembl is a joint project between European Molecular Biology Laboratory-
European Bioinformatics Institute (EMBL – EBI) and the Sanger Institute to develop a 
software system, which produces and maintains automatic annotation on selected 
eukaryotic genomes. Wellcome Trust primarily funded the project. The site has free 
access to all the data and software from the Ensembl project [107]. Using the Ensemble 
Mult-Blastview the intron of CRP was isolated [108]. The CRP intron is given in Figure 
3.2. 
 
The isolated intron information was then pasted into Clone Manager© from 
Scientific & Educational Software, Cary, North Carolina and this program designed the 
appropriate primers. One 5’primer and four 3’primers were designed. Table 3.1 presents 
the intron PCR primers. 
 
 
PCR Reaction Protocol 
 
The stock primers were reconstituted to working PCR primers, so that they would 
be fresh, this was accomplished by using 20µL stock and 380µL ddH2O. PCR reaction 
set up was made with a master mix of 17.75µL ddH2O, 10µL Mg Free Buffer, 4µL 
dNTP, 10µL MgCl2, 2.5µL 5´ primer, 2.5µL 3´ primer, 0.25µL Taq and 3µL DNA 
sample. Total volume was 50µL/tube. The Taq DNA Polymerase used was from 
Promega (M1661 in Stage Buffer B). Annealing temperature was set at 60º C. A Gradient  
Cycler PTC-225 Tetrad cycler (MJ Research, Waltham, MA) was programmed to 
execute the following formula:  
 
Step 1. 95° C for 2 minutes (to denature DNA) 
Step 2. 95° C for 1 minute 
Step 3. 60° C for 1 minute 
Step 4. 72° C for 2.5 minutes, then 
Step 5. Repeat Step 1, 39 times 
Step 6. 4° C 
Step 7. End 
A 1% agarose gel was used to assess amplification using 5µL of PCR product. 
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 GTAAGGGCCACCCCAGGCTATGGGAGAGATTTGATCTGAGGTATGGGGGTGGGGTCTAAG 
 ACTGCATGAACAGTCTCAAAAAAAAAAAAAAAAGACTGTATGAACAGAACAGTGGAGCAT 
 CCTTCATGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGTGTGTAACTGGA 
 GAAGGGGTCAGTCTGTTTCTCAATCTTAAATTCTATACGTAAGTGAGGGGATAGATCTGT 
 GTGATCTGAGAAACCTCTCACATTTGCTTGTTTTTGGCTCACAG 
 
 
Figure 3.2 CRP Gene Intron 
 
 
 
 
 
 
Table 3.1 Intron PCR Primers  
    
Label Sequence 
5 5´- GGG TCT AAG ACT GCA TGA AC -3´ 
3a 5´- CAC AGT GAA GGC TTT GAG AG -3´ 
3b 5´- GGA AGT ATC CGA CTC TTT GG -3´ 
3c 5´- TCC GAC TCT TTG GGA AAC AC -3´ 
3d 5´-AAC GGT GCT TTG AGG GAT AC -3´ 
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Preparation of Samples for Sequencing Protocol 
 
 The samples with positive amplification were identified from the gel and were 
then ethanol precipitated to pellet the DNA. 45µL PCR product was added to 19.25µL 
3M Sodium acetate (NaOAC) (12.3045 g Sodium acetate QS to 50 ml ddH2O) and 
128.5µL Ethanol (Absolute). Mixture was vortexed well, and then left in a -20º C freezer 
overnight. The next morning the samples were removed from the freezer and spun at 
13,000 rpm for 15 minutes to pellet the DNA. The supernatant was poured off and the 
pellet was allowed to air dry to evaporate the ethanol. The pellet was then reconstituted in 
20µL ddH2O and placed in a 57 º C water bath for 15 minutes to encourage the DNA 
back into the solution. A 0.8% agarose gel was used to run the samples with 3µL of 
loading dye to fluoresce the sample. The samples were run for 2/3 length of gel. 
Visualization to confirm band intensity was made with gel doc photo. The bands were 
then cut out of the gel and placed in appropriately labeled microcentrifuge tubes. Gel 
extraction was done using the QIAquick Gel Extraction Kit Protocol (Qiagen). Each gel 
slice was weighed and 3 volumes of Buffer QG (supplied in Qiagen Kit) to 1 volume of 
gel (100mg ˜ 100µL) were added to each sample tube. The tubes are then incubated in a 
50 º C water bath for 10 minutes. After DNA gel was dissolved completely, 1 gel volume 
of isopropanol was added and mixed. The DNA sample was applied to the QIAquick 
column in a clean microcentrifuge tube, and centrifuged for one minute. The flow-
through was then discarded and the column replaced in the tube. 0.5 ml of Buffer QG 
(supplied in Qiagen Kit) was added to column and centrifuged for one minute. This step 
removed all traces of agarose. To wash, 0.75 ml of Buffer PE (supplied in Qiagen Kit) 
was added to column and centrifuged for one minute. The flow-through was again 
discarded and centrifuged for an additional minute at 10,000 x g. The column is then 
placed in a clean microcentrifuge tube and the DNA eluted with 50µL of Buffer EB 
(supplied in Qiagen Kit) and centrifuged for one minute. The average eluated volume was 
48µL. The samples were then prepared for sequencing at the Molecular Resource Center 
(MRC) at the University of Tennessee Health Science Center (UTHSC) campus in 
Memphis, Tennessee. Samples were submitted as template/primer mixes, with the ratio of 
DNA/primer dependent on the type of template employed. A 0.5 flat top PCR tube was 
labeled with sample ID, primer used and investigators initials. In each tube 4.4µL of 
DNA extracted sample, 1.6µL of sequencing primer and 9.0µL ddH2O was added for a 
total of 12.0µL.   
 
 The MRC is a Center of Excellence at the UTHSC and provides the university 
with state-of-the-art technologies for molecular based research. The MRC with its core 
laboratory had a full range of trained personnel and equipment to assist the investigator 
with the sequencing of the intron DNA segment. Automated DNA sequencing is done by 
the BI Model 3130 XL Genetic Analyzers (Applied Biosystems, Foster City, CA). Four 
color fluorescence based sequencing was done based on the Sanger method [103, 109].  
 
 In the MRC, following the incorporation of the labeled dNTP in the extension 
products, the reactions were purified by gel filtration, dried down, re-suspended in 
formamide, and run on the analyzer. The run sequence submitted to the MRC was 340bp 
and the analyzer was capable of running an extension of over 700bp. The process took 
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about 48 hours to complete and the results were placed on a server and were downloaded 
and analyzed using ABI software supplied by Applied Biosystems, Foster City, CA.  
 
 
DNA Clean Up  
 
 When DNA failed PCR or sequencing, the sample was cleaned up using 
Phenol/Chloroform/Isopropyl (PCI). The PCI consisted of Phenol 25 ml; Chloroform 
24ml; Isoamyl alcohol 1 ml, which fit into a 50 ml Polypropylene centrifuge tube. A little 
of the liquid layered over the phenol was similarly layered over this mix to prevent 
moisture or evaporation. The Chloroform was also needed for the second step in the 
procedure. The three samples needing clean up were identified in the laboratory 
notebook.  
  
 The original snap cap tube with genomic DNA plus three snap cap tubes were 
used. Each of the 3 snap cap tubes was labeled with the sample DNA identification 
number. To the genomic DNA tube 1 ml PCI was added, care was taken to avoid the 
liquid layer top; the genomic DNA tube was vortexed well. After being centrifuged for 1 
minute at 13,000 rpm, the top layer was carefully pipetted to the appropriately labeled 
first snap cap tube. The steps were repeated again with 1 ml PCI added, vortexed, and 
centrifuged the genomic DCA tube and pipetted to the second tube. Then 1 ml 
Chloroform was added to the second tube, the sample was well vortexed, and centrifuged 
for 1 minute at 13,000 rpm. The top layer was pipetted and placed in the third snap cap 
tube. One ml Absolute Ethanol was added and inverted several times, until the formation 
of a DNA swirl was seen. The sample was allowed to set for 10 minutes at room 
temperature, then spun 1 minute at 13,000 rpm. The pellet was found and then the ethanol 
was carefully poured off and allowed to air dry, briefly. The excess alcohol was removed. 
100µL of DNA buffer (1:10 TE) was added to DNA pellet and vortexed for 5 seconds to 
re-hydrate pellet. The sample was then incubated at room temperature for 24 hours. The 
cleaned samples were then stored, when fully hydrated, at -20º for long-term storage. 
 
 
Databases 
    
 Established in 1988, the National Center for Biotechnology Information (NCBI) 
created public databases, has conducted research in computational biology, and has 
developed software tools for analyzing genome data, and disseminated biomedical 
information. This national resource supports a more comprehensive understanding of 
molecular processes and the links to genetic processes, information and dissemination of 
information affecting human health and disease [110]. The website provides biomedical 
and bioinformatics information, its mission is to aid researchers in three areas: basic 
research, database and software development and outreach and education.  
   
 Basic research is accomplished using a multi-disciplinary research group, 
concentrating on computational molecular biology. Database and software development 
consisted on GenBank DNA and sequencing database, building on sequences submitted 
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by individual laboratories worldwide; Entrez retrieval system for users to access vital 
background information on mapping, sequences and structural genetic data; and Blast, a 
program designed to execute a sequence match utilizing the entire DNA database using 
real-time information. 
 
 Applied Biosystem Group (ABI) is an operating group of Applera Corporation. 
ABI serves the microbiology industry and research communities by developing and 
marketing systems, consumables, software and services unique to molecular biology. 
Sequencing Scanner© version 1.0 is available free as a download from the company. This 
software displays the traces as thumbnails data files, allowing quick overview of the 
sequences looking for anomalies. It enables the researcher to view, edit, print and export 
the sequences. It is also useful in identifying failed chemical reactions, low signal 
strength, spikes and off scale peaks and delays or shifts in injection [111].  
 
 The length of the PCR products ranged from 165 to 215 continuous read length 
base pair, corresponding to introns containing 15 to 20 repeats (CA15 to CA 20). The 
CRP intron was successfully amplified from 29 of 29 (100%) of the DNA samples tested.  
 
 Sebastiani Network Model (SNM) Severity Score was designed using a Bayesian 
approach. This model assesses the relationship between historical clinical complications, 
current laboratory results and the risk of death in SCD patients [9]. The program that 
generated this network can be assessed at Bayesware Discoverer @ 
www.bayesware.com. Boston University has made available a website using the network 
model as a diagnostic tool to assist in identification of symptoms related to SCD severity. 
The severity score was calculated by providing clinical and laboratory data from each 
patient into the disease severity score calculator. The range of scores were 0 (least severe) 
to 1 (most severe) and the outcome measure for this score is the risk of death within 5 
years [9]. Supplemental tables with analysis and conditional probability tables that define 
the network are also available at the Boston University website [112]. The severity score 
is to be used as an adjunct to clinical decision-making.  
 
 
Statistical Analysis 
 
Statistical analysis was performed using Statistical Package for the Social Science 
(SPSS®) version 15 (SPSS Inc, Chicago, IL) and p < 0.05 was considered significant in 
all tests. Statistical analysis included descriptive statistics expressed as mean, mode, 
range and standard deviation.  
         
To project the minimum number of participants in each group that were needed to 
adequately power the study, the range of normal Hgb AA serum level CRP results were 
used to obtain an estimate of σ [113]. That information was then substituted to estimate 
the value of σ2 in the sample size equation to determine an approximate sample size. To 
achieve the minimum number of subjects per group it was estimated with a 95% 
confidence interval having a tolerable error of 3. The values of CRP ranged from 0.5 to 
3.0, where σ = range/4 = (3-.5) and E = 3/2 [113]. Using the formula 
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n = (Ζ∝/2)2σ2    ≅ 11 
E 2 
 
subjects per group was used to estimate sample size [85]. It is anticipated that 
approximately 30 patients will be needed to adequately power the analysis. 
 
Frequencies and percentages were run for all nominal level variables. Measures of 
central tendency were used to examine interval/ratio level variables, along with normality 
assessments. A common finding was the laboratory data; including the serum CRP levels 
were skewed. Because of this and the small sample size, non-parametric statistics were 
used to address the aims. 
 
 
Specific Aim One 
 
Describe and characterize two groups of patients with SCD, with (severe cases) 
and without (mild cases) the development of chronic organ dysfunction. The data were 
then used to assess and attempt to validate the predictive value of the SNM Severity 
Score in this sample population. Frequency distributions and parametric t-tests were used 
to describe and characterize the sample. The Disease Severity Score Calculator was used 
to obtain the SNM Severity Score [112]. The relationship of pulmonary jet velocity, 
GFR, 24° urine protein, LDH, CRP, Hgb levels, and evidence of clinical stroke, was 
examined using Spearman Rank Correlation Coefficient rho using SPSS software. 
 
 
Specific Aim Two 
  
Assess whether serum CRP levels differ between two groups of SCD patients, 
with (severe cases) and without (mild cases) the development of chronic organ 
dysfunction. The relationships between mild and severe patients with SCD and serum 
CRP levels were measured using a Chi-squared analysis and t-tests. 
 
 
Specific Aim Three 
 
Assess whether genotype profiles for a microsatellite repeat in the intron of the 
CRP gene between two groups of patients with SCD, with (severe cases) and without 
(mild cases) the development of chronic organ dysfunction. 
 
a. Identify the microsatellite repeats in the intron of the CRP gene for severe cases. 
b. Identify the microsatellite repeats in the intron of the CRP gene for mild cases. 
c. Assess whether the microsatellite repeat in the intron of the CRP gene is 
associated with serum CRP levels in the two groups of patients with SCD, (severe 
cases) and without (mild cases) the development of chronic organ dysfunction. 
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 The sequence tracing were analyzed with Sequence Scanner from Applied 
Biosystem Group (ABI). The tracing were first evaluated for anomalies and compared 
side by side. The CA repeats were visually calculated and verified by an independent 
evaluator. The relationships between mild and severe patients with SCD and evidence of 
the microsatellite SNP on the CRP gene were measured using a Chi-squared analysis, t-
tests and Spearman Rank Correlation Coefficient rho. 
 
 
Consideration of Human Subjects 
 
 The study received approval from The University of Tennessee Health Science 
Center Institutional Review Board (IRB). It had the full cooperation and support from the 
research department, staff and physicians at The University of Tennessee Cancer 
Institute. All IRB guidelines were maintained and the research results were stored 
separately from individual identifiers with restricted access. The research results for each 
subject were not in the medical records and other third parties such as employers or 
insurers did not have access to the research results. Only aggregate data will be used to 
report findings in publications and presentations. 
 
DNA was banked for future genetic studies. Ownership of the blood, data 
associated with it, data generated from analysis of it, and immortalized cell lines 
developed from the specimens belong to the University of Tennessee Cancer Institute. 
The samples were immortalized into a cell line; the storage of the samples will be 
indefinite. 
 
 This research study may provide valuable information about the risks of end-stage 
organ damage in adult sickle cell disease patients. At the time the data analysis of these 
samples was performed, findings did not have an impact on the participant’s health or 
treatment. Consequently, the results of this study were not shared with the subjects. 
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CHAPTER 4. RESULTS 
 
 
 The purpose of this study was to assess the utility of CRP polymorphism and 
serum levels as an independent risk factor for end-organ dysfunction in SCD. The study 
described and characterized two groups of adults with SCD (mild and severe) according 
to historical and clinical markers. An attempt was made to validate secondary organ 
dysfunction using the quantifiable SNM Severity Score [9]. The results are organized and 
presented by the study aims. 
 
 
General Description of the Sample 
 
All subjects were from an urban oncology/hematology center in the regional Mid-
South. Every SCD patient was screened for enrollment and was approached for 
participation if inclusion and exclusion criteria were met. Sixty patients were screened 
and 30 patients (50%) met enrollment criteria. Of those, 29 adults with SCD agreed to 
participate and were enrolled in the study. One subject who met enrollment criteria 
requested additional time to review consent forms at home, and enrollment had closed at 
the next appointment. Demographic information was gathered from chart review. Table 
4.1 summarizes the characteristics of the total sample. All of the subjects were of African 
American ethnicity.  
 
The historical demographic information was gathered from chart review. The total 
sample was categorized into two groups: mild and severe based on end-organ dysfunction 
and complications. The mild group was categorized by the absence of historical 
complications. Specifically, the mild group did not have any recorded history of acute 
chest syndrome, avascular necrosis, priapism, or retinopathy. One subject in the mild 
group on further investigation had a positive history of sepsis. Sepsis was not included in 
the exclusion criteria, and the data from the subject was included in the mild group for 
statistical analysis. Table 4.2 reports the frequency distribution of historical 
complications in the sample. 
 
All subjects were evaluated on complete blood count levels. Some examples of 
laboratory values, which typically are different from normal in this population, are Hgb, 
MCV and reticulocyte counts. Using a one-sample t-test, the mean for this sample 
population was compared to the reference values in the normal population. Table 4.3 
reports the laboratory values for the sample and the reference values for the normal 
population. Additionally, comparison values for the t-test comparisons are included since 
reference values are reported in a range. For the purposes of this study the comparison 
value was the medium point in the reference range. The study participants compared to 
the reference groups found hemoglobin was significantly lower than (p = 0.01) and MCV 
and platelet values were significantly higher (p = 0.03, and 0.02 respectively).  
 
 Table 4.4 reports laboratory values for the sample and reference values on 
additional laboratory tests used in the screening and care of adults with SCD. These tests  
39 
 
Table 4.1 Characteristics of Total Sample (n = 29) 
 
 Total Sample SD Range 
Age (years) 31.74 11.54 18-61.39 
Gender male [n (%)] 15 (51.7%)   
African-American [n (%)] 29 100%   
Weight (lbs) 153.22 38.78 103-262.00 
BMI (kg/m2) 24.52 06.09 18-43.20 
Systolic B/P (mm/Hg) 118.52 13.28 87-145.00 
    
    
Genotype Total Sample %  
SS 17 48.60  
SC 7 20.00  
Sß+ 2 06.90  
Sß0 3 10.30  
 
40 
 
Table 4.2 Frequency Distribution of Total Sample on Historical Complications from 
Chart Review 
 
Complications Frequency Percent n 
Acute Chest Syndrome 13 61.9% 29 
Avascular Necrosis 5 23.8% 29 
Sepsis 6 21.4% 29 
Priapism (males) 5 33.3% 15 
Retinopathy 13 61.9% 29 
Pain 24 82.8% 29 
 
Note: Subject numbers (n) vary. The presence or absence of historical complications for 
some participants could not be ascertained from the medical record. 
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Table 4.3 Comparison of Sample Laboratory Values for Total Sample (n = 29) as 
Compared to Reference Values from the Normal Population 
 
Laboratory test Mean SD Reference Value Range 
Comparison 
Value p value 
White blood count  
(109/L) 8.86 4.11 4.3-10.8 7.55 0.05 
Hemoglobin (g/dL) 9.46 1.95 14-18/male 15.00 0.01 
   12-16 female   
Hematocrit (%) 27.33 5.78 45-52 48.50 0.17 
Reticulocytes (%) 7.97 5.40 0.5-1.5 0.85 0.43 
MCV (µm3) 94.72 12.66 80-100 90.00 0.03 
Platelets (109/L) 371.55 200.15 150-450 300.00 0.02 
Hemoglobin F (%) 7.53 6.21 0.8-2 1.40 0.38 
 
Note: MCV = mean corpuscular volume, µm3 = cubic micrometer, SD = standard 
deviation, g/dL = grams per deciliter, L = liter, % = percent 
 
 
 
 
 
 
 
 
42 
 
Table 4.4 Comparison of Sample Laboratory Values for Total Sample (n = 29) Used 
in Screening and Care of Adults with SCD as Compared to Standardized Reference 
Values 
 
Laboratory test Sample Mean SD 
Reference 
Range 
 
Comparison 
Value 
p-
value 
B-type natriuretic  
peptide (mg/L) 26.22 20.45 0-100 100 0.34 
Ferritin (µg/L) 551.04 730.61 12-150 150 0.33 
Lactate  
dehydrogenase (U/L) 373.54 163.13 100-190 190 0.20 
Bilirubin (mg/dL) 2.19 1.72 0.3-1 1 0.23 
Blood urea nitrogen  
(mmol/L) 8.48 3.86 3.7-7.1 7.1 0.06 
Serum creatinine 
(mg/dL) 2.29 8.22 0.5-1.2 1.2 0.19 
Glomerular filtration  
rate (mL/min) 109.86 49.97 90-120 100 0.028 
24º urine protein  
(mg/dL/day) 224.09 195.81 150 150 0.12 
Total protein (gm/dL) 32.38 62.66 6-8.3 8.3 0.34 
Echo TRJV (m/s) 1.99 0.90 <2.5 <2.5 0.07 
Echo ejection  
fraction (%) 61.05 5.30 <40 >40 0.13 
 
Note: SD = standard deviation, mg/L = milligrams per liter, µg/L = microgram per liter, 
U/L = units per liter, g/dL = grams per deciliter, mmol/L = millimolars per liter, mL/min 
= milliliters per minute, mg/dL/day = milligrams per deciliter per 24º, gm/dL = grams per 
deciliter, TRJV = tricuspid regurgitate jet velocity, m/s = meter per second, % = percent 
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included; renal function tests, liver enzymes, C-reactive protein (CRP), and B-type  
natriuretic peptide (BNP), which are commonly used to evaluate secondary organ 
damage. A one-sample t-test was used to compare this sample to the normal population. 
Because reference values are reported in a range the comparison value was also reported 
in the table. The medium point in the range was chosen as the comparison value for all 
analysis. The only significant finding was the GFR (p = 0.028). The differences in GFR 
levels were expected because elevated GFR was an inclusion criterion for the severity 
group. In analyzing the ferritin level of the total sample, the mean was 551.04 µg/L ± 
730.61 (range 19.00-2751.70 µg/L). Three subjects were on chronic transfusion therapy 
and nine subjects were receiving intermittent transfusions. The BMI was significantly 
higher in the sample n = 29, (p = 0.03), as was systolic blood pressure (p = 0.03).  
   
 
Specific Aim One 
 
 Aim one sought to describe and characterize the end-organ dysfunction of two 
groups of sickle cell disease patients with and without the development of chronic organ 
dysfunction. The mild group consisted of individuals with no documentation of end-
organ dysfunction. The severe group consisted of individuals with documentation of 
pulmonary hypertension, renal end-organ dysfunction and/or cerebral vascular accident. 
 
 
Description and Characteristics 
 
Three organ systems were evaluated in assigning subjects to sub-severity groups: 
pulmonary hypertension (pulmonary), renal end-organ dysfunction (renal), and cerebral 
vascular accidents (CVA). Nine subjects (42.9%) meet the criteria for assignment to the 
severe sub-group due to pulmonary hypertension. Pulmonary hypertension was evaluated 
by historical evidence from echocardiogram report in the subjects’ charts. A tricuspid 
regurgitation jet velocity of greater than or equal to 2.5 m/s was considered abnormal. 
 
 There were six (28.6%) subjects with clinical evidence of renal end-organ 
dysfunction and they were assigned to sub-group renal. A historical 24-hour urinalysis 
was used to categorize end-stage renal dysfunction, a GFR of less than 60% or a urine 
protein greater than 500 mg was considered abnormal.  
 
Six (28.6%) of the subjects had CVA evidence and were assigned to the sub-
group CVA. The cerebral vascular severity sub-group had clinical evidence of damage by 
documentation of abnormal brain MRI/MRA results. Table 4.5 reports the characteristics 
of the sample by mild and severe groups.  
 
 To compare the two groups (mild vs. severe) on laboratory data, independent t-
tests were conducted. Pain and transfusion therapy were not included as part of the 
criteria to assign subjects to severity groups. Three subjects enrolled into the mild group 
had historical documentation of intermittent transfusion therapy for pain. Three subjects 
in the severe group were on chronic transfusion therapy and five subjects had 
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Table 4.5 Characteristics of Mild and Severe Groups 
 
 Mild  Severe  
Age (years) 
Age Range (years) 
32.71 ±14.30 
(18.67-61.39)  
29.69 ± 8.9 
(18.67-50.22)  
Gender-male [n (%)] 2 (25%)  13 (61.9%)  
     
Genotype n % n % 
SS 5 62.5 12 57.1 
SC 1 12.5 6 28.6 
Sß+ 1 12.5 2 09.5 
Sß0 1 12.5 1 04.7 
Hydroxyurea Tx 1 12.5 16 76.2 
 
Notes: Hydroxyurea Tx = hydroxyurea therapy   
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documentation of intermittent transfusion therapy. Table 4.6 presents a comparison of the 
two groups on traditional serum laboratory values.  
 
Several variables were used to determine assignment into the severity sub-groups. 
Table 4.7 reports additional comparisons of laboratory values between the mild vs. severe 
groups using biomarkers of end-organ dysfunction.  
 
 Additional analysis was explored after finding no differences in laboratory values, 
except MCV, bilirubin and platelets, between mild vs. severe groups. A secondary 
question was formulated regarding the possibility that the organ of dysfunction may play 
a role in the analysis. The severe group was divided into subgroups based on the type of 
end-organ dysfunction. The sub-group of pulmonary hypertension (n = 9) had a mean 
TRJV of 2.85 m/s ± 0.27, compared to the mild group (n = 8) with a TRJV of 1.71 m/s ± 
0.7 (p = 0.000).  
 
The sub-group of renal end-organ dysfunction (n = 6) had a mean GFR of 74 % ± 
37.49 and 24° urine protein level of 408.5 mg/L/day  ± 215.58 compared to the mild 
group (n = 8) with a mean GFR of 117.64 % ± 40.91 and 24° urine protein level of 98.99 
mg/L/day ±  40.05. Evidence of other secondary complications was reported with events 
of acute chest syndrome, sepsis, and retinopathy. Figure 4.1 reports the frequency of 
these complications by end-organ dysfunction sub-group. 
 
 Evidence of priapism in the pulmonary end-organ dysfunction sub-group was 
found in 2 of 9 subjects (22.2%), for the renal sub-group there was 2 of 6 subjects 
(33.3%) and in the CVA sub-group 1 of the 6 subjects (16.6%). Only one subject from 
the renal sub-group had a history of leg ulcers.  
 
The cerebral vascular severity group had clinical evidence of dysfunction 
identified by documentation of abnormal brain MRI/MRA results. Additionally, 2 of 9 
subjects in the pulmonary sub-group and 3 of 6 subjects (50%) of the renal sub-group had 
abnormal brain MRI/MRA. Historical evidence of AVN was found in 2 of 8 subjects 
(22.2%) of the pulmonary sub-group, 1 of 6 subjects (16.6%) of the renal sub-group, and 
2 of 6 subjects (33.3%) of the CVA sub-group. Additionally, retinopathy was 
documented from an ophthalmologist report, which was part of the screening process in 
this clinic setting. Retinal damage was found in 7 of 8 subjects (87.5%) of the pulmonary 
sub-group (one missing value in this group), 3 of 3 subjects (50%) in the renal sub-group, 
and 3 of 3 subjects (50%) of the CVA sub-group. 
 
Treatment therapy was collected from the medical records of each subject. Figure 
4.2 reports the distribution of hydroxyurea and transfusion therapy within the severity 
sub-groups.  
 
 While not the focus of this study, another complication in the adult SCD 
population is pain. Pain was classified as positive if the subject had documentation in the 
medical record of pharmacologically treated pain episodes at the last follow-up clinic 
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Table 4.6 Comparison of Mild and Severe Groups on Traditional Serum 
Laboratory Values 
 
 Mild n=8 Severe n=21  
Laboratory test Mean SD Mean SD p-value 
White blood count (109/L) 10.31 3.4  8.31 4.3 0.250 
Hemoglobin (gm/dL) 9.27 1.7  9.52 2.1 0.765 
Hematocrit (%) 27.34 4.9  27.37 6.2 0.958 
MCV (µm3) 84.46 8.0  98.63 11.9  0.005* 
Hemoglobin F (%) 5.48 5.3  8.39 6.5 0.275 
Reticulocytes (%) 10.14 6.4  7.14 4.9 0.186 
Platelets (109/L) 338.5 90.0  384.14 229.4 0.592 
Ferritin (µg/L) 433.15 647.1  595.94 770.1 0.601 
*p< 0.005 
Note: SD = standard deviation, 109/L = 109 per liter, gm/dL = grams per deciliter, % = 
percent, MCV = mean corpuscular volume, µm3 = cubic micrometer, µg/L = microgram 
per liter  
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Table 4.7 Comparison of Mild and Severe Groups on Clinical Values Used to 
Evaluate End-organ Dysfunction 
 
 Mild n = 8 
 Severe n = 21  
 Mean SD 
 Mean SD p-value 
LDH (U/L) 417.00 219.50  361.80 146.95 0.48 
Bilirubin (mg/dL) 3.35 2.42  1.74 1.16   0.02* 
BNP (mg/L) 27.15 21.38  25.85 20.64 0.88 
BUN (mmol/L) 6.11 2.97  9.38 3.83   0.04* 
Serum creatinine (mg/dL) 0.64 0.15  2.91 9.65 0.52 
Urine creatinine (mg/dL) 61.19 20.63  80.69 38.56 0.19 
24° creatinine (mg/dL/day) 915.92 335.17  1174.72 465.26 0.16 
GFR (mL/min) 117.62 40.91  106.90 53.64 0.62 
24° Urine Protein 
(mg/dL/day) 98.99 40.04 
 271.74 210.89   0.03* 
Total Protein (gm/dL) 6.88 2.83  42.10 71.65 0.18 
EF (%) 63.00 4.98  60.31 5.37 0.23 
TRJV (m/s) 1.71 0.70  2.11 0.94 0.30 
*p< 0.005 
Note: SD = standard deviation, LDH = lactate dehydrogenase, U/L = units per liter, BNP 
=  B-type natriuretic peptide, mg/L = milligrams per liter, BUN = blood urea nitrogen, 
mmol/L = millimolars per liter, mg/dL = milligrams per deciliter, mg/dL/day = 
milligrams per deciliter per 24º, mL/min = milliliters per minute, gm/dL = grams per 
deciliter, EF = ejection fraction, % = percent, TRJV = tricuspid regurgitate jet velocity, 
m/s = meter per second  
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Figure 4.1 Frequency of Historical Evidence of ACS, Sepsis, and Nephropathy by 
End-organ Dysfunction Sub-groups within the Severe Group 
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Figure 4.2 Frequency of Treatment Options by End-organ Dysfunction Severity 
Sub-groups 
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visit. A majority of the subjects in both the mild and severe groups were positive for pain. 
For the mild group 6/8 (75%) had pain compared to 18/21 (85.7%) in the severe group.  
Pain was analyzed by end-organ dysfunction severity sub-groups and found 8 of 9 
subjects (88.8%) of the pulmonary sub-group, 100% of the renal sub-group subjects and  
4 of 6 subjects (66.6%) of the CVA sub-group had pain. Three subjects in the CVA sub-
group with pain (n = 4) had intermittent or chronic transfusion therapy (75%).  
 
 
Sebastiani Network Model (SNM) Severity Score Validation 
 
 The SNM Severity Scoring system [9] used to compare this sample, integrated 
documented disease complications and results of selected laboratory tests. This Bayesian 
network model was built on associations of variables and assumes “death” as the central 
outcome. This is a newly developed model and has not been independently validated with 
prospectively gathered data. The purpose of incorporating this model into the analysis 
was to compare our clinical assessment of severity to the network model severity score.  
 
 Historical complications are considered an independent risk factor for severity 
evaluation. The charts that were reviewed to collect the gathered information included the 
childhood complications. There were 18 variables used in this network model of 
prediction. These variables included age, acute chest syndrome, priapism, avascular 
necrosis, sepsis, blood transfusions, LDH, MCV, gender, CVA, systolic blood pressure, 
WBC, genotype, bilirubin, reticulocyte count, and pain. An individual severity score was 
calculated for each subject using the “disease severity score calculator” found at 
www.bu.edu/sicklecell/downloads/Projects [112]. The possible range of scores was from 
zero to one with higher scores indicating greater risk of 5-year mortality. Figure 4.3 
demonstrates the wide variability of the SNM Severity Scores within the sample 
population.     
 
 There was no significant difference (p = 0.51) between the SNM Severity Score 
for the mild group [0.275 ± 0.302 (n = 8)] as compared to the severe group [0.362 ± 
0.319 (n = 21)]. The mild group did have 7 of 8 subjects (87.5%) of the scores below the 
0.5 value [9]. The mild group had one subject who was an outlier due to a historical 
finding of sepsis, which was not included as a criterion when assigning subjects to the 
mild and severe group. In the SNM Severity Score analysis, sepsis was identified as a 
strong predictor of disease severity. Figure 4.4 reports the distribution of SNM Severity 
Scores by mild vs. severe sub-groups. When looking at the severe end-organ dysfunction 
sub-groups separately, there were no significant correlation between the assigned SNM 
Severity Score and prognostic clinical markers used to assign subjects to a severity sub-
groups. 
 
What was most interesting was that the pulmonary sub-group had the widest 
range of severity scores, while the mild group had the smallest range. It is also interesting 
that all four groups had subjects with low severity scores, so variability was on the higher 
end of the scale.  
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Figure 4.3 SNM Severity Scores for Sample Population 
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Figure 4.4 Boxplot of SNM Severity Score by Mild and Severity Sub-groups 
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There was no significant difference in severity scores between the mild and the 
severe sub-groups. Comparing the mild mean severity score 0.275 ± 0.302 vs. pulmonary 
0.331 ± 0.332 (p = 0.720), renal 0.345 ± 0.346 (p = 0.727), and CVA 0.433 ± .321 (p = 
0.364). The severity scores were also analyzed with a t-test, grouped by 
 hemoglobin genotype, Hgb SS and Hgb Sβ0 vs. the Hgb SC and Hgb Sβ+. No significant 
differences were found with SS and Sβ0 mean of 0.319 ± 0.280 vs. SC and Sβ+ mean of 
0.3 ± 0.334 (p = 0.875). The four average clinic profiles, one from the mild group and 
one from each sub-group are provided in Table 4.8. The profiles had complete data sets 
of all 18 variables for calculation of SNM Severity Score.  
 
 When the mild patient with a history of sepsis was excluded from the analysis, 
data are slightly skewed positively with the SNM Severity Scores by visual assessment. 
However, the difference in average score between subjects with mild cases or severe 
cases of organ dysfunction remained non significant (t-test 1.538, p = 0.136). Table 4.9 
reports the relationship between the SNM Severity Score and complete blood counts of 
all subjects. One subject was missing the hemoglobin F % level. The SNM Severity 
calculator automatically assigned a score for the missing value.  
   
 An attempt to validate the SNM Severity Score with this sample, Spearman Rank 
Correlation rho was performed to look for an association with biomarkers of chronic 
organ dysfunction. The primary purpose was to determine if any biomarker for end-organ 
dysfunction was associated with the SNM Severity Score. The results are reported in 
Table 4.10 and showed no association. The LDH was missing in three subjects, two of 
the subjects were in the mild group and one subject was in the severe group. 
 
 Sample data on the 18 variables used to calculate the SNM severity score was 
compared to the primary data source, Cooperative Study of Sickle Cell Disease (CSSCD) 
sample cited in Sebastiani et al [9]. Table 4.11 presents the means and standard 
deviations of the study sample and CSSCD data. The study sample had 70% on 
hydroxyurea therapy while the CSSCD group had 27% of the sample on hydroxyurea 
therapy. 
 
 
Specific Aim Two 
   
 The second aim addressed whether the mild group and severe groups differed on 
serum CRP levels. The reference serum CRP level is < 10 mg/L but levels ≥ 3 mg/L have 
been linked to low grade inflammation and an increase risk of cardiovascular disease 
[85]. An independent t-test was conducted to evaluate if baseline serum CRP levels 
would be higher in subjects with evidence of chronic organ dysfunction. The mean serum 
CRP levels of the total sample population were 6.89 mg/L ± 8.22 (range 0.3 to 31.30). 
The CRP data was then statistically analyzed using a t-test to compare the mild vs. severe 
groups. There was no significant difference found between mild and severe groups,  
t(26) = 0.031, p = 0.976. The analysis of the means, standard deviations and ranges for 
the total sample, mild and severe groups and end-organ dysfunction sub-groups are  
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Table 4.8 Disease SNM Severity Scores for Mild, Sub-group Pulmonary 
Hypertension, Sub-group Renal Dysfunction, and Sub-group CVA  
 
Variable Mild Pulmonary Renal CVA 
ACS No Yes Yes Yes 
Age Range 40-50 18-40 40-50 18-40 
Bilirubin 2.8 0.81 5 2.1 
Blood Transfusion No No No Yes 
LDH 478 168 409 278 
MCV 88.4 96 90 97.3 
Pain No Yes Yes Yes 
Priapism No No Yes Yes 
Reticulocytes 13.09 4.95 8.1 3.49 
Sepsis No No Yes Yes 
Gender Female Female Male Male 
Stroke No No No Yes 
Systolic B/P 108 113 108 125 
WBC 8.8 8.6 13.3 5.3 
Hgb Genotype SS SS SS SS 
AVN No No Yes Yes 
SNM Severity Score 0.312 0.318 0.994 0.841 
 
Note: Subjects were classified in the current study by: Pulmonary hypertension by TRJV 
≥ 2.5 m/s, Renal end-organ dysfunction by GFR ≤ 60% or 24° Protein ≥ 500, CVA by 
historical evidence from MRI/MRA. ACS = acute chest syndrome, LDH = lactate 
dehydrogenate, MEC = mean corpuscular volume, B/P = blood pressure, WBC = white 
blood count, Hgb = hemoglobin, AVN = avascular necrosis, SNM = Sebastiani Network 
Model 
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Table 4.9 Associations between Complete Blood Count Laboratory Values and SNM 
Severity Score, Spearman Rank Correlation Coefficient rho 
 
Variable rho p-value 
White Blood Count 0.13 0.51 
Hemoglobin -0.04 0.86 
Hematocrit -0.11 0.58 
Reticulocytes 0.15 0.43 
MCV 0.27 0.16 
Platelets 0.10 0.63 
Hemoglobin F % 0.21 0.30 
 
Note: n = 29, MCV = mean corpuscular volume, % = percent 
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Table 4.10 Associations between Chronic Organ Dysfunction Measures and SNM 
Severity Scores, Spearman Rank Correlation Coefficient rho 
 
Variable rho p-value 
Lactate dehydrogenase 0.01 0.86 
Bilirubin 0.15 0.53 
Blood urea nitrogen -0.08 0.72 
Serum creatinine 0.10 0.67 
24° urine creatinine -0.24 0.29 
Glomerular filtration rate -0.16 0.48 
24° urine protein -0.00 0.99 
Total protein 0.32 0.14 
Echo TRJV -0.01 0.98 
 
Note: n = 21, except lactate dehydrogenase (n = 20), TRJV = tricuspid regurgitate jet 
velocity 
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Table 4.11 Comparison of the Study Sample with SCCDC Data on Variables 
Used to Calculate SNM Severity Score 
 
 
Current study 
 n = 29 
CSSCD 
 n = 3380 
Variable   Mean   SD Mean  SD 
Age (years) 31.14 11.58 20.00 14.4 
Bilirubin (mg/dL) 2.19 1.72 2.71 1.89 
BUN level (mmol/L) 8.48 3.86 9.36 5.36 
Serum creatinine 
(mg/dL) 2.29 8.22 0.70 0.64 
Hemoglobin (g/dL) 9.45 1.95 9.13 1.81 
Hemoglobin F (%) 7.53 6.21 6.12 5.78 
LDH (U/L) 374.54 163.13 459.51 206.34 
MCV (µm3)  94.72 12.66 87.42 8.75 
Platelets (109/L) 371.55 200.15 399.30 131.17 
Reticulocytes (%) 7.97 5.4 9.56 5.85 
Systolic B/P (mmHg) 118.52 13.28 105.70 12.35 
WBC  (109/L) 8.84 4.12 11.17 3.31 
 
 
Note: CSSCD indicates Cooperative Study of Sickle Cell Disease. SD = standard 
deviation, BUN = blood urea nitrogen, mmol/L = millimolars per liter, mg/dL = 
milligrams per deciliter, gm/dL = grams per deciliter, % = percent, LDH = lactate 
dehydrogenase, U/L = units per liter, MCV = mean corpuscular volume, µm3 = cubic 
micrometer, 109/L = 109 per liter, B/P = blood pressure, mmHg = millimeters of mercury, 
WBC = white blood count  
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reported in Table 4.12. There was one missing baseline serum CRP level in the severe 
group. 
 
Distribution of the serum CRP levels showed 67.86% (19 of 28 subjects) had a 
baseline level of ≥ 3 mg/L, which is the cut point used to determine cardiovascular risk. 
Table 4.13 reports the frequency of serum CRP levels categorized as < 3 mg/L, 3 to10 
mg/L, and > 10mg/L cut points.   
 
 Correlation analysis was used to explore relationships between serum CRP values 
and clinical severity markers that are elevated in adult SCD patient. These markers 
included; WBC, hemoglobin, MCV, Hgb F%, reticulocyte counts, TRJV, GFR, 24° urine 
protein, documented CVA and SNM Severity Score. Table 4.14 reports the results of the 
analysis between serum CRP levels and biomarkers of clinical severity in adults with 
SCD. No significant relationships were found between these markers and baseline serum 
CRP levels. 
 
 
Specific Aim Three 
 
 Mild and severe groups were compared on the CRP intron microsatellite CA 
repeat. Twenty-nine subjects were included in the identification and description of the 
genotype profiles for microsatellite. DNA sequencing was accomplished on all the 
samples obtained. The microsatellite repeats in the intron of the CRP gene were analyzed 
using ABI’s Sequencing Scanner© version 1.0 software. The software displayed the 
traces as thumbnails data files, allowing quick overview of the sequences looking for 
anomalies. The sequences were reviewed and edited for clarity. An independent 
researcher skilled in this technique verified the sequence determination. 
 
 The distribution range of the CA repeat was 14 to 20. The readable sequence 
length was 165 to 215 base pairs. Table 4.15 reports the distribution of the CRP 
microsatellite polymorphism recorded as a CA repeat sequence for the total sample 
population.   
 
To examine potential interactions between CRP genotype, baseline CRP and 
severity status, the microsatellite length scores were classified into two groups. The 
CAn=14-16 were allocated to the category of low allele (CA)low group with a range of 14-16 
repeats. The high allele (CA) high group was defined as ≥ 17 repeats with a range of 17-20 
repeats. Figure 4.5 reports the distribution and frequency of the CRP gene microsatellite 
CA repeat by mild and severe groups. The mild group had five subject in the CAlow 
category and three subjects in the CAhigh. The severe group had 15 in the CAlow category 
and six subjects in the CAhigh.  
 
 Correlation analyses to elucidate the possible mediating role of CRP 
microsatellite allele length to historic and clinical markers of chronic organ dysfunction 
were performed. The microsatellite length alone did not show a significant association  
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Table 4.12 Serum C-Reactive Protein Levels by Total Sample, Mild and Severe 
Groups, and the End-organ Dysfunction Sub-groups 
 
 
 
 n Mean SD Range 
Groups     
Total Sample  28 6.89 8.22 0.3-31.3 
Mild  8 6.96 4.18 2.1-14.3 
Severe 20 6.85 9.47 0.3-31.3 
     
Severe Subgroups     
Pulmonary   9 2.00 1.60 0.3-5.5 
Renal  6 9.15 11.05 1.0-27.6 
Cerebral Vascular  5 12.84 12.74 1.6-31.3 
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Table 4.13 Distribution of Serum C-Reactive Protein Levels by Mild and Severe 
Groups 
 
 C-Reactive Protein Levels 
Groups < 3 mg/L 3-10 mg/L > 10 mg/L 
Mild  (n = 8) 2 4 2 
Severe (n = 20) 9 7 4 
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Table 4.14 Associations between Serum CRP and Laboratory and Clinical 
Biomarkers of Severity in Adults with SCD Using Spearman Rank Correlation 
Coefficient rho 
 
Category/Marker Variables rho p-value 
Standard SCD Laboratory White Blood Count -0.048 0.808 
 Hemoglobin 0.075 0.705 
 MCV -0.086 0.664 
 Hgb F% -0.244 0.219 
 Reticulocytes 0.248 0.204 
Pulmonary HTN  TRJV -0.323 0.093 
Renal Dysfunction  GFR -0.226 0.248 
 24° Urine Protein -0.049 0.804 
Cerebral Vascular CVA 0.033 0.867 
Severity Validation Severity Score 0.127 0.521 
CRP Genotype Allele Group 0.147 0.456 
 
Note: n = 28 except for Hgb F % (n = 27) 
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Table 4.15 Distribution of CRP Polymorphism CA Repeat for Total Sample 
 
CA Repeats Count # Percent % 
14 1 3.40 
15 15 51.70 
16 4 13.80 
17 5 17.24 
18 2 6.89 
19 1 3.40 
20 1 3.40 
CAlow 
CAhigh 
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Figure 4.5 Distribution and Frequency of CRP Gene Microsatellite CA Repeats by 
Mild and Severe Groups   
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with baseline serum CRP levels or historic and clinical chronic organ dysfunction 
markers.  
 
Spearman Rank Correlation Coefficients were computed between CRP CAlow and 
CAhigh repeat groups and the laboratory biomarkers. The results of the correlation 
analyses presented in Table 4.16 illustrated that 2 of 10 correlations were statistically 
significant and were greater than or equal to 0.35. GFR was the only biomarker of end-
organ dysfunction that was significantly associated with CRP CAhigh allele group. In 
general, the results suggest that CAhigh alleles are not associated with inflammation that 
contributes to end-organ dysfunction. 
 
When grouped into (CA)low and (CA)high categories there was a significant 
association between the allele and GFR % and the hemoglobin levels. The boxplot for the 
variables GFR and CAlow and CAhigh allele groups, as shown in Figure 4.6, indicates that 
the two variables were linearly related. The association of CAhigh repeats was associated 
with GFR level decreases. While not statistically significant 44% (4 of 9 subjects) in the 
pulmonary hypertension severity sub-group were also categorized into the CAhigh allele 
group. 
 
 An additional polymorphism identified in the literature distinguishes the CA 
repeat as heterozygous vs. homozygous CA16/20 [12]. This sample did not identify this 
polymorphism in the sequence runs. A new finding in the sequence pattern for the study 
sample was a heterozygous polymorphism, found in the third CA repeat on two sequence 
tracings. One sample was heterozygous for CA17/19 and one sample was CA18/20. Neither 
of these heterozygous polymorphisms was identified in the literature. 
  
 To analyze the tracings each sequence was evaluated and identification was made 
to clearly mark the start of the CA repeats. The obvious repeats were then counted. An 
independent analysis verified the CA count. For each tracing the sequence falls apart after 
the repeats. It is possible that many of the subjects were heterozygous for the CA repeat 
length and accounted for the difficultly in evaluation of heterozygous status. Figure 4.7 
demonstrates the region where the CA repeats begin and identifies the problem area at the 
end of the run. Sequence runs were done with 3’ and 5’ primers to clarify the sequence 
but new primers were not designed to totally alleviate the problems area.  
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Table 4.16 Associations between Clinical Laboratory Markers and CRP Allele 
Groups, Spearman Rank Correlation Coefficient rho  
 
Category/Marker Variables rho N p-value 
Standard SCD Laboratory White Blood Count 0.049 29 0.801 
 Hemoglobin -0.392 29 0.035* 
 MCV 0.067 29 0.73 
 Hgb F (%) -0.063 27 0.757 
 Reticulocytes 0.134 29 0.489 
 CRP 0.147 28 0.456 
Pulmonary HTN TRJV 0.125 29 0.512 
Renal Dysfunction GFR -0.401 29 0.031* 
 24-hour Urine Protein -0.058 29 0.765 
Cerebral vascular CVA -0.175 29 0.369 
Severity Validation Severity Score 0.076 29 0.696 
*p < 0.05 
Notes: SCD = Sickle cell disease, MCV = mean corpuscular volume, Hgb F = 
hemoglobin fetal, % = percent, HTN = hypertension, TRJV = tricuspid regurgitate jet 
velocity, GFR = glomerular filtration rate, CVA = cerebral vascular accident 
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Figure 4.6 Boxplot of Glomerular Filtration Rate by CAlow and CAhigh Repeat 
Groups   
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Figure 4.7 Sample Sequences with Defined Start and Problem Area Identified   
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CHAPTER 5. DISCUSSION AND LIMITATIONS 
 
 
The purpose of this study was to assess the utility of CRP polymorphism and 
serum levels as an independent risk factor for end-organ dysfunction in SCD. The study 
described and characterized adults with SCD according to historical and clinical markers. 
The subjects were then classified into 2 groups, mild and severe, based on their clinical 
status. Their clinical status was based on chart review, current laboratory results and 
genetic samples. The data were used to calculate a severity score using the Sebastiani 
Network Model SNM (SNM) [9] and to explore the applicability to the sample. Further 
investigation assessed the relationship between the mild and severe groups on two 
variables; serum baseline CRP levels, and a genetic dinucleotide microsatellite in the 
intron of the CRP gene. Chapter five provides a discussion of the findings related to each 
specific aim, the strengths and limitations of the study and explores implications for 
future nursing practice and research. 
      
 The sample consisted of 29 subjects, recruited from a regional urban 
oncology/hematology clinic. The subjects were under the direct care of one hematologist, 
who has implemented a standard management protocol for all individuals with SCD. 
There were eight mild cases gathered for evaluation. Mild cases were defined as those 
with no historical evidence of secondary complications and current laboratory findings 
were within the normal ranges.   There were 21 severe cases recruited. The severe cases 
were defined as having evidence of end-organ dysfunction. In addition, the severe cases 
were further categorized by the type of end-stage organ dysfunction: pulmonary, renal, 
and cerebral vascular. Classification of pulmonary hypertension was determined from an 
echocardiogram, with results indicating a TRJV ≥ 2.5 m/s. Nine subjects were in this sub-
group. End-stage renal dysfunction was classified by one of two historical laboratory 
indicators, GFR ≤ 60% or 24º protein level of ≥ 500 mg/day. Six subjects were in this 
sub-group. Historical evidence of cerebral vascular accident was used for the third sub-
group, which had six subjects. 
 
 Adults with SCD have statistically significant differences in baseline blood counts 
compared to standardized values [6]. Our study using the total sample demonstrated 
similar baseline clinical blood count values in white blood count, hemoglobin, 
reticulocyte count, MCV, platelets and hemoglobin F % levels as have been found in 
other national surveys of SCD patients [6, 39, 114]. All differences noted between sample 
SCD patients and reference values are well documented and consistent with the literature 
for the SCD population. 
 
 As expected, in the analysis of the total sample, elevations in bilirubin and LDH 
levels were noted. Baseline serum bilirubin levels in SCD patients are often elevated as a 
consequence of hemolysis, making this biomarker unreliable as a measure of liver disease 
[6, 115]. Hepatic dysfunction is a recognized secondary complication frequently 
associated with iron overload from transfusion treatment [115, 116]. Ferritin levels were 
elevated for the sample, mean of 551.04 μg/L ± 730.61, (range of 19-2751.7). Subjects 
receiving intermittent or chronic transfusion therapy were 34.48% (n = 10). There is 
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some controversy regarding how well serum ferritin levels correlate with hepatic iron 
concentrations [117]. The LDH mean for this sample was 375.54 U/L ± 163.13. The 
elevation of LDH may reflect the presence of liver disease, and dysfunction may be 
explained by a history of sepsis, sequestration, cholecystitis, cirrhosis, obstruction, [116, 
118] or viral infection [117]. Clear patterns of hepatic dysfunction have been difficult to 
characterize with standard clinical markers, however this laboratory finding is used in the 
SNM Severity Score.    
 
 Laboratory findings are also labile in response to renal dysfunction in SCD 
patients. Elevated findings for this sample included blood urea nitrogen (8.48 mmol/L ± 
3.86), serum creatinine (2.29 mg/dL ± 8.22), 24º protein (224.09 mg/dL/day ± 49.97), 
and total protein (32.38 gm/dL ± 62.66). The major contributors to these abnormal results 
are the inability to concentrate urine, incomplete form of distal renal tubular acidosis and 
impaired potassium metabolism [6, 119]. Current data show that genetic factors such as 
inherited β-gene cluster haplotype [6, 53], may help identify “at risk” groups for renal 
dysfunction. This could be explored in future studies. 
 
 Clinical evidence of retinopathy was also gathered from the sample population. 
The highest percent of this sequela is generally found in Hgb SC (33%) [6]. Retinopathy 
was found in 44.82% (n = 13) of the subjects. One possible explanation is that most of 
these subjects (96.5%, n = 28) had completed an independent comprehensive eye exam as 
part of the clinical baseline evaluation process, which improved the diagnostic 
probability.        
  
 
Specific Aim One 
 
 The first specific aim was to describe and characterize two groups of sickle cell 
disease (SCD) patients with (severe cases) and without (mild cases) the development of 
chronic end-organ dysfunction. These data were then used to validate the predictive value 
of the SNM Severity Score. The mild group consisted of individuals with no 
documentation of end-organ dysfunction. The severe group consisted of individuals with 
documentation of pulmonary hypertension, renal end-organ dysfunction and/or cerebral 
vascular accident. Clinical events such as history of acute chest syndrome, pneumonia, 
avascular necrosis, leg ulcers, cerebral vascular accident, and priapism were controlled in 
the screening process by classifying the mild cases as free from these historical 
complications. Laboratory variables included: white blood cell, hemoglobin, hematocrit, 
reticulocytes, MCV, platelets and hemoglobin F % levels. There were no significant 
differences between groups (mild and severe) on these variables with the exception of 
MVC (mean of mild group, 84.46 µm3 vs. mean severe group 98.63 µm3, p = 0.005). 
These results may be attributed to the high % of severe group subjects treated with 
hydroxyurea therapy. 
 
While not statistically significant, the mean of Hgb F % was also higher in the 
severe group. This is an interesting finding because higher Hgb F % are associated with 
lower clinical severity [4], but cannot fully explain the diversity of SCD phenotype. This 
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was probably influenced by the high percentage of subjects in the severe group, 76.2%  
(n = 16) using hydroxyurea as a treatment regime. Hydroxyurea was only noted in one 
subject in the mild group. Hydroxyurea increases the Hgb F% and has been found to 
decrease morbidity and mortality [51]. 
 
 When evaluating baseline organ dysfunction, neither group had significant 
differences in laboratory levels of: LDH, BNP, serum creatinine, urine creatinine, 24º 
creatinine, GFR, and total protein. From the historical echocardiogram results there were 
no differences between the mild and severe group for ejection fraction or tricuspid 
regurgitate jet velocities. The severe group had significantly different levels of BUN and 
24º Protein levels (BUN, p = 0.021 and 24º protein levels, p = 0.031). Another unusual 
finding was the difference between the mild and severe groups on bilirubin levels. The 
mild group was significantly higher p = 0.021 than the severe group. Baseline serum 
bilirubin levels in SCD patients are often elevated as a consequence of hemolysis, making 
this biomarker unreliable as a measure of liver disease [6]. This biomarker may also be 
affected by the increase in Hgb F %. The literature supports the association of increases 
in concentrations of Hgb F % and decreases in bilirubin levels [51]. All of these 
biomarkers have been studied as useful in the prediction of severity in SCD patients.  
 
Severity is frequently assessed by hemoglobin genotype. While there was 
numerous support that the genotypic hemoglobinapathy Hgb SS was associated with the 
most complications [4, 5, 8, 50, 76] but secondary complications arise in all of the 
hemoglobin genotypes. In the severe group 57.1% were Hgb SS (n = 12) but also 
represented were Hgb SC 28.6% (n = 6), Hgb Sβº 9.5% (n = 2) and Sβ+ 4.8% (n = 1). 
Likewise, in the mild group Hgb SS was represented by 62.5% (n = 5), Hgb SC 12.5%  
(n = 1), Hgb Sβº 25% (n = 2), demonstrating that hemoglobin genotype alone cannot 
determine severity.  
   
Predicting clinical severity in SCD has been elusive. The ability to predict disease 
expression could be beneficial to patients and healthcare providers in managing this 
disease process. A useful method of pre-determining the risk of secondary complications 
could allow individualized tailoring of therapy and education [4, 5, 9, 50]. The SNM 
Severity Score was designed to integrate historical clinical events and current laboratory 
finds into an objective quantifiable severity score. The SNM Severity Score is based on 
the risk of mortality within five years as the measured outcome [9].  
 
The SNM Severity Score was calculated on the study sample by using each 
subject’s historical information and current selected laboratory results. There were 18 
variables used in this model of prediction. There were no significant relationship found 
between SNM Severity Scores and the current study severity classification. Using the 
SNM Severity Score to determine severity in the study sample found one subject in the 
mild group at a very high risk 0.996 of mortality within five years. There were 17 of 21 
subjects in the severe group with documented end-organ dysfunction that had a SNM 
Severity Score < 0.5, a less than 50% chance of mortality in the next five years. 
Therefore, the SNM Severity Score may serve as a useful tool in predicting mortality, but 
may not be as useful for studies exploring the secondary complications of SCD. Accurate 
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assessment and evaluation of the secondary complications are essential to determine 
treatment options for patients.  The SNM severity score could not be validated in this 
sample. The classification developed in this study may more accurately identify patients 
who will have secondary complications. These individuals may need closer health 
screening, additional surveillance and aggressive therapeutic intervention.  
 
 
Specific Aim Two 
  
Specific aim two was to explore the relationship of baseline serum CRP levels in 
two groups (mild and severe) with respect to evidence of clinical end-organ dysfunction. 
The mean serum CRP levels of the total population were 6.89 mg/L ± 8.22, (range 0.3 to 
31.20). T-tests found no significant differences between the mild vs. severe groups,   
t(26) = 0.031, p = 0.976.  
 
The relationship between CRP serum levels > 3 mg/L and low grade 
inflammation and pathogenesis for cardiovascular disease has been well documented [90, 
91, 120]. The role of CRP in SCD patients is still under scrutiny and reference norms for 
the SCD population have not been determined. Bourantas et al demonstrated increased 
serum CRP levels in steady state SCD patients [21]. Another study found the mean CRP 
concentration of Hgb SS patients to be 9.12 mg/L (range, 0.02-52.6). This study found 
similar results with a mean 6.89 mg/L ± 8.22 (range, 0.3-31.3) regardless of hemoglobin 
genotypes (SS, SC, Sβ°, and Sβ+). Singhal and colleagues found that CRP concentrations 
were increased above 5 mg/L even when symptom free in SS and SC genotype patients 
when compared to a healthy control AA group [121]. This was also supported by Mohan 
and colleagues with 64 SCD patients and 42 matched AA controls [113] and Hedo and 
colleagues with 73 Hgb SS patients [122]. One study demonstrated an increase in CRP in 
the prodromal phase of vaso-occlusive crisis (n = 10) [123]. Recently, researchers have 
looked for an association between CRP levels and hypermetabolism, as it affects growth 
and development in SCD patients [124]. A gap in the literature remains on the 
relationship of CRP to secondary complications and specifically end-organ dysfunction 
that effect the adult SCD population.    
 
Analysis with the literature has also been difficult since there is a natural increase 
in CRP levels with age. Many of the studies involving SCD and CRP levels had small 
sample sizes and combined adults, adolescents and children in the sample population. In 
the SCD literature on CRP children or adolescents [121, 125], two studies included a 
combination of adolescents (age 12 years) and adults [21, 122], one study used adults    
(n = 64) [113], while a third study did not report the age of the sample [123]. Factor 
analysis revealed no statistical differences between the mild and severe groups.  
 
Several factors may have contributed to these findings. One factor may have been 
the presence of several outliers, CRP levels > 10 mg/L in both the mild (n = 2) and severe 
(n = 4). When evaluating CRP as a contributor to cardiovascular risk the CRP levels are 
evaluated for baseline levels over 3mg/L. This study found that 67.86% (n = 19 of 28 
subjects) had CRP levels greater than 3 mg/L. Possibly reflecting a sub-clinical 
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inflammatory response. When analyzed by mild and severe there were no differences; in 
fact, 75% (6 of 8 subjects) mild cases had CRP levels over 3 mg/L and 55% (11 of 20 
subjects) severe cases had CRP levels over 3 mg/L. The role of sub-clinical inflammation 
may still be critical to the SCD population but not reflected in this small sample size. It is 
curious, if there could be a skewed effect because of the high percentage of elevated 
baseline results in this sample population. Interestingly, while it is yet to be determined if 
elevated serum CRP levels contribute to SCD severity, elevations were observed in this 
SCD sample.   
 
Age and pain were confounding variables that may have affected serum CRP levels, as 
well as other clinical and laboratory values. The severity group had a mean age of 31. 37 
mg/L ± 10.68 but the range was 19.79 to 58.9. Age could be a confounding and 
misleading variable in assessment of severity of SCD. As adults with SCD survive into 
the 4th and 5th decade of life, the ageing process will naturally affect CRP levels. CRP is a 
biomarker that increases with the age of the patient. 
 
Serum C-reactive protein levels are also affected by pain. Pain is an acute and 
ongoing problem for adults with SCD. Pain was purposely not evaluated or described in 
this sample population, although presence or absence of acute pain and treatment was 
captured. Painful episodes are considered a strong predictor of severity [9, 50]. An 
immense amount of a healthcare provider’s time is focused on management of pain, but 
may overshadow the subliminal signs of impending end-organ dysfunction. This study 
attempted to emphasize that secondary complications might be occurring in the absence 
of pain. There were three subjects in the severity group that had no recorded pain or 
treatment for pain episodes.  
   
 Another factor contributing to the lack of differences in CRP levels may have 
been the collection of several CRP levels from chart review. The medical record reflected 
a baseline status, but this may not have accurately captured current inflammatory status. 
More stringent control and prospective collection of the serum CRP sample could 
strengthen the validity of the sample results. Several confounding variables could be 
controlled when collecting prospective serum CRP levels such as excluding; red cell 
transfusions, peripheral vascular disease, long-term medications such as hydroxyurea, 
oral contraceptives, and analgesia use in the past month. Under these conditions it may 
have been extremely difficult, if not impossible, to collect samples. 
 
 
Specific Aim Three 
  
 The goal of specific aim three was to conduct pilot bench research to explore a 
microsatellite repeat in the intron of the CRP gene. DNA structure is affected by base-
paired Cytosine (C) and Adenine (A) or CA repeats within the structure of the gene [12]. 
An increase in the number of CA repeats in this microsatellite in the intron of the CRP 
gene have been associated with an increase in the baseline serum CRP levels [12, 102]. 
The study identified the number of the microsatellite repeats in each subject and tested 
the possibility that a high number of polymorphic CA repeats contributed to an elevation 
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of serum CRP levels. The literature has supported the hypothesis that low grade 
inflammation from elevated CRP levels contributes to cardiovascular disease [90, 91, 
120], but this hypothesis has not been tested for its contribution to other end-organ 
dysfunctions or in the SCD population.   
 
 This study was unable to find an association between baseline serum CRP levels 
and allele frequency with this small sample and there was great variability of the CRP 
levels. Serum CRP levels are influenced by episodic and sub-clinical inflammation 
stimuli. It has been demonstrated in other studies [21, 113, 122, 125] that SCD patients 
have a higher baseline CRP level, most likely due to episodic vascular occlusions and 
subclinical micro vascular occlusions, than the general population. During inflammation, 
cytokines and other pro-inflammatory markers may up-regulate the CRP gene. It may be 
possible that CAhigh  alleles affect CRP levels when inflammatory markers are triggered. 
 
 In several studies the concentration of serum CRP was elevated and was shown to 
be influenced by genetic variants [14, 18, 126], including the CA dinucleotide repeat 
found in the intron of the CRP gene [12, 102]. An association between CRP SNP’s 
(rs1800947) [127] and (rs2794520) [128] and basal CRP expression has been described. 
However, these SNP’s do not have sufficient support or validation to be classified as the 
sole genetic cause [14]. More research was needed to evaluate the effect of genetic CRP 
variants and any influence they exert on serum CRP levels. 
 
 The CA repeat microsatellite was selected because the distribution of alleles 
differs significantly between Caucasians and African Americans [102] and the SCD 
population is predominately AA. According to Szalai et al the three most common 
genotypes (CA16, CA16/21, and CA21) were only found in 20% of all African-Americans 
[12]. Albeit the current study had a small total sample size, but the frequency of high 
repeat alleles was similar with 31%, (9 of 29 subjects). Further evidence from this study 
supported that differences in alleles are associated with differences in baseline CRP 
within races [102]. 
 
 A significant negative association was found between the CAhigh allele group and 
GFR levels (rho = -0.401, p = 0.031). GFR levels are not an indicator of inflammation 
but may be an indirect measure of the inflammation that occurs in the kidney of a SCD 
patient. GFR may be under less control of the labile inflammation process and only 
reflects the damage that has already occurred in the kidney. It may also be a chance 
association. While not statistically significant, 44% (n = 4 of 9 subjects) of the sub-group 
pulmonary hypertension were also classified into the CAhigh allele group. Pulmonary 
hypertension results when there is a lost of elasticity as the red blood cells sickle. The 
sickling causes microvascular occlusions and myocardial cell damage. While the exact 
pathogenesis is multifactorial, the reduced blood flow and the resulting ischemia are a 
major factor in the damage to the myocardium [6, 63]. Again, CRP levels are not a 
marker for pulmonary hypertension but may reflect damage that has already occurred in 
the heart muscle.      
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Study of this CA microsatellite is not without detractors. Russell, et al concluded 
that CRP SNP’s more accurately define serum CRP expression than the length of the 
intronic repeat microsatellite [127]. Szalai et al noted that the CA allele could be in 
linkage disequilibrium with an unidentified section in the proximal promoter region of 
the CRP gene or an unknown gene [102]. It has been suggested that it may be important 
to obtain more indirect evidence of genetic influence prior to embarking on further 
genetic studies with family studies. Given the evidence of different allele frequencies in 
African-Americans, further exploration between matched controls and SCD patients may 
provide more evidence that this microsatellite has an affect on CRP levels. 
Polymorphisms in the CRP gene affecting serum CRP levels could lead to the 
development of a predictive model to assist in the identification of risk for secondary 
complications of SCD. 
 
 
Strengths and Limitations 
 
 Strengths of the study include the comprehensive description of the clinical 
parameters of the sample due to the baseline screening protocol implemented by this 
clinic. The physician involved in the study has attempted to complete a baseline 
assessment of all SCD patients in this clinic. This assessment included; physical exam, 
extensive history review, screening serum blood levels on target organs (heart, kidney 
and liver), echocardiogram from an independent cardiologist, MRI/MRA of the brain, 
and retinal exam from an independent ophthalmologist. The results from this study 
suggested the need for a standardized comprehensive screening protocol for all SCD 
patients. Furthermore, the study indicates a need for accurate medical records beginning 
in childhood to capture all historical complications and events.  
 
An additional strength was the willingness of African-Americans to participate in 
medical research. African Americans are frequently underrepresented in research trials. A 
study by Corbie-Smith  and colleagues found African Americans expressed a greater 
distrust of healthcare professionals but the study did not evaluate willingness to 
participate [129]. Another recent study, (Caucasian n = 460, African American n = 257), 
measuring willingness to participate found that African Americans scored lower than 
Caucasians (27% vs. 39%, p = 0.001) [130]. The two variables strongly influencing the 
decision to participate in medical research are distrust toward medical researchers and a 
perceived chance of experiencing injury [130, 131]. There is a gap in the literature 
regarding African American willingness to participate specifically in genetic research. 
Interestingly, although not designed to answer this questions, this study showed that 
African Americans are willing to participate in genetic research, even when there was no 
direct impact to their health. The subject’s willingness may have stemmed from their 
view of the professional competences of the investigators and from satisfaction with the 
physician and the care their received. From anecdotal conversation, another factor in their 
willingness may be related to the severity of the disease and that little research is being 
conducted on adults with SCD.    
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 Several methodological limitations are associated with this study. One major 
limitation of the study was the small sample size. The convenience sampling is 
considered a weak method but necessary given the small population size and the 
limitation of one geographic location. The small sample population restricts the use of 
randomization or random assignment for non-treatment descriptive studies, but external 
and internal validity are compromised with this approach. All of the comparisons in this 
study suffered from a lack of statistical power but this pilot work may stimulate research 
in other directions. Statistical analysis was restricted because the mild group was 
underrepresented. The inability to find mild cases points to a SCD population where the 
majority of patients experience some type of secondary complications in their life span. 
 
It has been established that hydroxyurea changes the natural course of SCD [51]. 
Hydroxyurea therapy was recorded as a nominal (yes/no) variable for this study, but the 
length of therapy was not collected. It was unknown if hydroxyurea treatment was 
initiated in the pediatric setting, and medical records did not reflect an accurate length of 
therapy. Within the last five to ten years hydroxyurea has been used in select children 
with severe phenotype without randomized supporting literature. There is now a 
randomized trial involving children using hydroxyurea that is ongoing [132]. It is yet to 
be determined if hydroxyurea therapy initiated in early childhood can ameliorate the 
presentation of SCD in adults. Further research is ongoing to determine the extent that 
hydroxyurea changes the natural course of SCD. This therapy will have to be included as 
a confounding variable in future studies. 
 
Another potential limitation was the fact that the principle investigator (PI) was a 
novice bench researcher. To modify this limitation the PI attended the Summer Genetic 
Institute at the National Institute of Health, did an independent study in DNA extraction 
and polymorphism analysis at the bench at the University of Chicago, and worked with a 
bench researcher at the University of Tennessee Health Science during genetic analysis. 
While the sequencing was successful the evaluation may have influenced the results. 
Each sequence was evaluated by analyzing the tracings. Identification to clearly mark the 
start of the CA repeats was made on each tracing. Then the obvious repeats were counted. 
An independent analysis was done to verify the CA count. In each case the sequence falls 
apart after the repeats. It is possible that many of the subjects were heterozygous for the 
CA repeat length and could have accounted for the difficulty in evaluation of 
heterozygous status. An alternative method of evaluation of the intron would be to 
amplify the segment containing the repeat and judge the number of repeats based on the 
size of the amplicon (personal communication with Dr. Alex Szalai, August 12, 2008).   
 
One genetic feature identified as a risk factor is the inherited β-gene cluster 
haplotype [6, 53], this information was not gathered for this study. Another biomarker for 
renal dysfunction being explored is albuminuria levels, which were not available in this 
sample [53, 80]. 
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Additional Findings 
  
 Fragmentation of care is a concern in this population [133]. This study sample 
was taken from an urban clinical site that serves a large regional area. Therefore, some 
subjects may experience hospitalizations outside the large urban hospital associated with 
the clinic. There may be several reasons for the fracturing of care including 
transportation, extended wait periods in the urban ER, and hostile interaction with 
healthcare providers unfamiliar with SCD. The biggest challenge for the hematologist is 
to receive accurate and informative documentation from hospitalizations. This study 
found 53.57% (n = 15) subjects had elevated ferritin levels. Medical record information 
documented chronic transfusion therapy for 3 of the subjects. Five subjects had 
documentation evidence of intermittent red blood cell transfusions. Seven subjects had no 
medical record history that could explain an elevation of ferritin levels. It can only be 
conjecture that these subjects are receiving some type of transfusion therapy outside of 
direction of the hematologist.       
 
 Another demonstration of the fragmentation of care is that in a retrospective chart 
review done prior to initiation of this study the clinic population of SCD patients was 
161. Sixty patients were screened during the enrollment phase over a six-month time 
period. However, only 29 patients enrolled met inclusion/exclusion criteria. The 
recommended follow-up clinic appointment for this clinic is every six months to monitor 
for complications and laboratory tests. Of the 31 patients screened but not enrolled, 15 
exhibited signs or symptoms of beginning end-organ dysfunction but did not meet the 
stringent inclusion criteria. Several patients with a clinic visit in the screening period 
lacked the necessary laboratory or clinical tests to meet inclusion/exclusion criteria, 
demonstrating the fragmentation of care. This indicates that numerous patients are not 
adequately utilizing health care services or are seeking care at another facility without 
requesting medical records be forwarded.  
 
 There has been a call for adequate representation of African Americans in clinical 
trials and research [130, 131]. Only one patient that was approached for participation did 
not sign the consent. A study by Shavers, et al demonstrated that the differences in the 
patient’s willingness to participate in research are related to the trust they have in the 
medical provider [131]. The physician in this project had established a trust relationship 
with the SCD patients in the clinic and provided the necessary entree to the patients for 
the investigator. A frequent comment from subjects was “I’m glad research is going on to 
help SCD patients”.       
 
 
Theoretical Implications 
 
 The implementation of the study was based on the Interaction Model of Client 
Health Behavior [35, 37], which assumes relationships between Elements of Client 
Singularity (CRP genotype and serum blood levels), Elements of Client Professional 
Interaction (severity scores and groups), and Elements of Health Outcomes (end-organ 
dysfunction). Risk research reveals that many aspects of Client Singularity (genotype and 
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phenotype) and Client Professional Interaction (severity assessment and distrust of 
healthcare professionals) are relevant to patients. Sickle cell disease is a lifelong chronic 
illness that greatly impacts patients. This study has described and evaluated the risk of 
secondary complications and end-stage organ dysfunction. Healthcare providers must be 
equipped with risk assessment tools and knowledge in order to engage a patient during 
the Client Professional Interaction phase of this theory. Health information, obtained and 
discussed during the Client Professional Interaction, is important in predicting severity of 
SCD. According to the Interaction Model, health information has a direct impact on the 
Element of Health Outcomes, specifically clinical health status indicators, severity of 
healthcare problems and adherence to recommended care regime. Under this model, the 
relevance of risk related to health care information (severity score) to the adult with SCD 
will influence the patient utilization of healthcare services (treatment options), and patient 
satisfaction with care. As treatment options advance toward individualized therapy and 
gene therapy, more research will be needed to validate the theory that increased risk 
health information positively impacts the utilization of healthcare services.  
 
 
Clinical Practice Implications 
 
 Several studies have proposed and attempted to describe severity of the SCD 
patient [3, 4, 9, 50, 122]. Recently the most promising severity score has been SNM, 
using mortality as the outcome of measure. For nursing implications one valuable tool 
would be to establish a standardized screening protocol. This protocol would involve a 
battery of baseline clinical findings and laboratory testing that is needed to fully evaluate 
the heath status of adults with SCD. Without accurate information and assessment of end-
organ damage, an accurate severity score or classification cannot be determined. This 
protocol would involve evaluation of pulmonary, renal, cerebral vascular, retinal and 
vascular (for priapism, leg ulcers and AVM) systems. The protocol should also involve a 
system to transfer historical and acute events from pediatric settings and rural hospital 
admissions. Healthcare providers must have confidence in the status of the patient’s 
condition before discussions about risk can be broached with a patient. This confidence is 
essential to maintaining a trust relationship between patient and healthcare provider. 
 
 A second nursing implication would be to establish a trust relationship to assist 
patients in the effective utilization of health care services. Adults with SCD face major 
adjustment difficulties in dealing day to day with an unpredictable chronic illness. Some 
areas that have been identified by patients are anxiety about health, dependence on pain 
medication, disabilities, disruption of quality of life and conflict with healthcare 
providers [133]. A proposed screening protocol involves extensive testing frequently 
outside the hematology clinic setting. Nursing should be available to coordinate and 
facilitate acquisition of the proposed screening assessments. A patient’s active 
involvement will also be needed to agree to adherence to screening and therapy decisions. 
While not an outcome of the study nursing must also take the initiative to eliminate 
discrimination in the health care setting regarding SCD patients and their dependence on 
pain medications and utilization of ER facilities. Better understanding of this disease 
process and its secondary complications would equip the nurse to provide the necessary 
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care needed for adults with SCD. Conflict with healthcare providers should never be 
identified as a barrier to care for SCD patients.  
 
 Finally, SCD may be one of the first genetically transmitted diseases to make 
major inroads in gene therapy and stem cell research because of the single gene base pair 
substitution. Nurses with genetic knowledge and understanding will be essential if they 
are going to interact with patients undergoing research procedures. Research towards 
more effective therapy or a cure will not be possible without the active support of the 
SCD population. Nursing must be prepared to facilitate this research with interventions to 
overcome the barriers SCD patients face in utilization of healthcare services. This is 
especially important in a population that has identified “conflict with healthcare 
providers” as a major obstacle to care [133, 134].  
  
 
Recommendations for Additional Research 
 
 This pilot study established a foundation for future investigation of the 
microsatellite in the intron of the CRP gene. This allele has been shown to be variable 
among ethnic groups and more frequently found in the African American population. A 
larger sample size selected from all SCD patients, not just mild and severe, and matched 
for race control group is suggested. The study was unable to support the hypothesis that 
the microsatellite repeat allele in the intron of the CRP gene indicated the propensity to 
develop inflammation as measured through the serum CRP levels. Timing of the 
collection of serum CRP may need to be more closely evaluated or a comparison of 
serum levels during baseline and acute events may give a more complete picture of CRP 
expression in the SCD patients. More comprehensive studies are needed to establish 
associations between the high CA repeat microsatellite allele and baseline CRP or 
markers of end-organ dysfunction. The incorporation of stringently controlled and 
prospectively gathered serum CRP samples would enhance the study design and help 
validate any association.  
 
 Although reported associations suggest that several polymorphisms are 
significantly correlated with baseline CRP levels [135], it is possible that the observed 
associations are in strong linkage disequilibrium with yet unidentified regions. Future 
research could also assess other common single-nucleotide polymorphisms that have 
been identified in the literature, such as 3872A allele, 2667C allele, and the 790T allele 
[15].  
 
 
Conclusion 
 
The contribution of this study was to further characterize the adult SCD 
population regarding the pathophysiology of secondary end-organ dysfunction. It 
explored the possibility of further research regarding CRP and a polymorphism of the 
CRP gene by providing pilot data on a microsatellite in the intron of the CRP gene. The 
study was unable to provide support for the use of serum CRP as a biomarker of severity 
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in adults with SCD. Although the evidence of a correlation between CRP alleles and GFR 
was found in this pilot sample, the relationship was not strong. Additionally, it was 
unable to validate the use of a SNM Severity Score as a model of prediction for end-
organ dysfunction when compared to the clinical findings of end-organ dysfunction 
found in the sample.  
 
 This study does inform and support the direction of future research by 
establishing baseline information regarding CRP in the adult with SCD. It also 
documents the different types of severity and secondary complications encountered by 
the healthcare provider in caring for SCD patients. Numerous questions remain regarding 
the interaction of serum CRP, genetic expression of CRP and its mechanisms with end-
stage organ dysfunction. Further genetic regulation of the expression of CRP levels still 
needs to be explored. 
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